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This publication presents the data and findings of the risk assessment on the new psychoactive 
substance 4-fluoroisobutyrylfentanyl (4F-iBF) (N-(4-fluorophenyl)-2-methyl-N-[1-(2-
phenylethyl)piperidin-4-yl]propanamide), carried out by the extended Scientific Committee of the 
EMCDDA on 7 and 8 November 2017.  
The Risk Assessment Report, which was submitted to the European Commission and the Council of 
the European Union on 14 November 2017, examines the health and social risks of the substance, 
information on international trafficking and the involvement of organised crime, as well as a 
consideration of the potential implications of subjecting the substance to control measures.  
4-Fluoroisobutyrylfentanyl is the nineteenth new psychoactive substance to be risk assessed under 
the terms of Council Decision 2005/387/JHA. 
On the basis of the Risk Assessment Report on a new psychoactive substance, and, on the initiative 
of the European Commission, the Council may decide that the substance should be subject to control 
measures across the Member States. This decision is adopted in the final stage of the three-step 
process — early warning, risk assessment and control of new psychoactive substances — 
established by the Council Decision 2005/387/JHA. This legal framework allows the EU institutions 
and Member States to act on all new and potentially threatening narcotic and psychotropic drugs 
which appear on the European drug scene, with the EMCDDA and Europol, in collaboration with their 
respective networks, playing a central role in the early detection of such substances as well as the 
harms caused by their use — information that underpins risk assessment, and, ultimately, decision-
making.  
In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 
4-fluoroisobutyrylfentanyl in Schedule I of the Single Convention on Narcotic Drugs of 1961 based on 
a recommendation by the World Health Organization. This recommendation was substantially 
supported by European data provided by the EMCDDA.  
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The EMCDDA has been assigned a key role in the detection and assessment of new drugs in the 
European Union under the terms of a Council Decision 2005/387/JHA on the information exchange, 
risk-assessment and control of new psychoactive substances. 
It establishes a mechanism for the rapid exchange of information on new psychoactive substances 
and provides for an assessment of the risks associated with them in order to permit the measures 
applicable in the Member States for the control of narcotic and psychotropic substances to be applied 
also to new psychoactive substances. 
The three-step process involves information exchange/early warning, risk assessment and decision-
making (see below). More detailed information can be found in the section ‘Action on new drugs’ of 
the EMCDDA’s website: www.emcdda.europa.eu/activities/action-on-new-drugs  
 
  
EMCDDA actions on monitoring and responding to 
new drugs  
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Europol–EMCDDA Joint Report on a new psychoactive substance: N-(4-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)isobutyramide — in accordance with Article 5 of Council Decision 
2005/387/JHA on the information exchange, risk assessment and control of new psychoactive 
substances 
In March 2017, the EMCDDA and Europol examined the available information on a new psychoactive 
substance N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide, commonly known by the 
abbreviation 4-fluoroisobutyrylfentanyl (4F-iBF), through a joint assessment based upon the following 
criteria: (1) the amount of the material seized; (2) evidence of organised crime involvement; (3) 
evidence of international trafficking; (4) analogy with better-studied compounds; (5) evidence of the 
potential for further (rapid) spread; and (6) evidence of cases of serious intoxication or fatalities. 
The EMCDDA and Europol agreed that the information available on 4-fluoroisobutyrylfentanyl 
satisfied criteria 4 and 6. The two organisations therefore concluded that sufficient information has 
been accumulated to merit the production of a Joint Report on 4-fluoroisobutyrylfentanyl as stipulated 
by Article 5.1 of the Decision. Accordingly, the NFPs, the Europol national units (ENUs), the EMA and 
the World Health Organization (WHO) were formally asked to provide the relevant information within 
six weeks from the date of the request, i.e. by 6 June 2017. 
The resulting Joint Report on 4-fluoroisobutyrylfentanyl was submitted to the Council, the Commission 
and the EMA on 3 July 2017. The report concluded that the health and social risks, caused by the use 
of, the manufacture of, and traffic in 4-fluoroisobutyrylfentanyl, as well as the involvement of 
organised crime and possible consequences of control measures, could be thoroughly assessed 
through a risk assessment procedure as foreseen by Article 6 of Council Decision 2005/387/JHA. 
The full text of the Joint Report can be found at: 
www.emcdda.europa.eu/publications/joint-reports/4f-ibf 
  
Europol–EMCDDA Joint Report on 4F-iBF (N-(4 
fluorophenyl)-N-(1-phenethylpiperidin-4-
yl)isobutyramide) — a summary 
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Introduction  
This Risk Assessment Report presents the summary findings and the conclusion of the risk 
assessment carried out by the extended Scientific Committee of the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) on the new psychoactive substance N-(4-fluorophenyl)-2-
methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (commonly known as 4-
fluoroisobutyrylfentanyl). The report is intended for policy makers and decision makers in the 
institutions of the European Union. 
The report has been prepared and drafted in accordance with the conceptual framework and the 
procedure set out in the risk assessment operating guidelines (1). It is written as a stand-alone 
document, which presents a summary of the information considered during the detailed analysis of 
the scientific and law enforcement data available at this time. The conclusion section of the report 
summarises the main issues addressed and reflects the opinions held by the members of the 
Scientific Committee. A list of the information resources considered by the Scientific Committee, 
including a detailed technical report on 4-fluoroisobutyrylfentanyl, is provided below.  
The risk assessment has been undertaken in compliance with Article 6 of Council Decision 
2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new 
psychoactive substances (2) (hereafter ‘Council Decision’). The Council Decision establishes a 
mechanism for the rapid exchange of information on new psychoactive substances (hereafter ‘EU 
Early Warning System’ (3)) that may pose public health and social threats, including those related to 
the involvement of organised crime. Thus, it allows the institutions of the European Union and the 
Member States to act on all new narcotic and psychotropic substances (4) that appear on the 
European Union drug market. The Council Decision also provides for an assessment of the risks 
                                                          
(1)  EMCDDA (2010), Risk assessment of new psychoactive substances: Operating guidelines, Publications Office of the 
European Union, Luxembourg. Available at: http://www.emcdda.europa.eu/html.cfm/index100978EN.html 
(2) OJ L 127, 20.5.2005, p. 32. 
(3) The information exchange mechanism laid down by the Council Decision is operationalized as the European Union 
Early Warning System on New Psychoactive Substances (‘EU Early Warning System’). It is operated by the 
EMCDDA and Europol in partnership with the Reitox national focal points and Europol national units in the Member 
States, the European Commission, and the European Medicines Agency. 
(4) According to the definition provided by the Council Decision, a ‘new psychoactive substance’ means a new narcotic 
drug or a new psychotropic drug in pure form or in a preparation; ‘new narcotic drug’ means a substance in pure form 
or in a preparation that has not been scheduled under the 1961 United Nations Single Convention on Narcotic Drugs, 
and that may pose a threat to public health comparable to the substances listed in Schedule I, II or IV; ‘new 
psychotropic drug’ means a substance in pure form or in a preparation that has not been scheduled under the 1971 
United Nations Convention on Psychotropic Substances, and that may pose a threat to public health comparable to 
the substances listed in Schedule I, II, III or IV. 
Risk Assessment Report on a new psychoactive 
substance: N-(4-fluorophenyl)-2-methyl-N-[1-(2-
phenylethyl)piperidin-4-yl]propanamide (4-
fluoroisobutyrylfentanyl; 4F-iBF) 
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associated with these new psychoactive substances so that, if necessary, control measures can be 
applied in the Member States for narcotic and psychotropic substances (5). 
4-Fluoroisobutyrylfentanyl was formally notified on 26 August 2016 by the EMCDDA on behalf of the 
Slovenian national focal point, in accordance with Article 4 of the Council Decision. The notification 
related to the collected sample of 5 grams of white powder that was test-purchased as part of the EU 
co-funded RESPONSE project. Following an assessment of the available information on 4-
fluoroisobutyrylfentanyl, and, in accordance with Article 5 of the Council Decision, on 3 July 2017 the 
EMCDDA and Europol submitted a Joint Report on 4-fluoroisobutyrylfentanyl (6) to the Council of the 
European Union, the European Commission, and the European Medicines Agency (EMA). Taking into 
account the conclusion of the Joint Report, and, in accordance with Article 6 of the Council Decision, 
on 14 September 2017 the Council formally requested that ‘the risk assessment should be carried out 
by the extended Scientific Committee of the EMCDDA and be submitted to the Commission and the 
Council within twelve weeks from the date of this notification’. 
In accordance with Article 6.2, the meeting to assess the risks of 4-fluoroisobutyrylfentanyl was 
convened under the auspices of the Scientific Committee of the EMCDDA with the participation of 
four additional experts designated by the Director of the EMCDDA, acting on the advice of the 
Chairperson of the Scientific Committee, chosen from a panel proposed by Member States and 
approved by the Management Board of the EMCDDA. The additional experts were from scientific 
fields that were either not represented, or not sufficiently represented on the Scientific Committee, 
and whose contribution was necessary for a balanced and adequate assessment of the possible risks 
of 4-fluoroisobutyrylfentanyl, including health and social risks. A further four experts participated in the 
risk assessment: two experts from the Commission, one expert from Europol, and one expert from the 
European Medicines Agency (EMA). The meeting took place on 8 November 2017 at the EMCDDA in 
Lisbon. The risk assessment was carried out on the basis of information provided to the Scientific 
Committee by the Member States, the EMCDDA, Europol, and the EMA. A list of the extended 
Scientific Committee, as well as the list of other participants attending the risk assessment meeting, is 
annexed to this report (page 52). 
For the risk assessment, the extended Scientific Committee considered the following information 
resources: 
 Technical report on N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-
yl]propanamide (4-fluoroisobutyrylfentanyl) (Annex 1);  
 EMCDDA–Europol Joint Report on a new psychoactive substance: N-(4-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyrylfentanyl) (6); 
 Open source information including scientific articles, official reports, grey literature, internet 
drug discussion forums and related websites (hereafter ‘user websites’);  
 Additional information provided during the course of the risk assessment by the participants; 
 The EMCDDA operating guidelines for the risk assessment of new psychoactive substances 
(1); and, 
                                                          
(5) In compliance with the provisions of the United Nations Single Convention on Narcotic Drugs, 1961, and the United 
Nations Convention on Psychotropic Substances, 1971. 
(6) EMCDDA (2017), EMCDDA–Europol Joint Report on a new psychoactive substance  N-(4-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyrylfentanyl), EMCDDA, Lisbon. Available at: 
http://www.emcdda.europa.eu/publications/joint-reports/4F-iBF 
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 Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk 
assessment and control of new psychoactive substances (2). 
 
Finally, it is important to note that this risk assessment report contains a discussion of the available 
information on serious adverse events such as acute intoxications (typically presenting to hospital 
emergency departments) and deaths associated with 4-fluoroisobutyrylfentanyl. Such information is 
critical to the identification of emerging toxicological problems associated with new psychoactive 
substances within the European Union. In this context, it is important to recognise that the capacity to 
detect, identify, and report these events differ both within and between Member States. In the past 
few years, programmes have been introduced in some Member States to strengthen these capacities. 
The EMCDDA’s toxicovigilance system, which is a central component of the EU Early Warning 
System, has also been strengthened resulting in more information being available regarding serious 
adverse events associated with new psychoactive substances. Nonetheless, it is likely that these 
events remain under-detected and under-reported. 
Physical, chemical and pharmacological description 
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4-
fluoroisobutyrylfentanyl or 4F-iBF) is structurally related to fentanyl, which is a propionamide. 4-
Fluoroisobutyrylfentanyl contains one basic nitrogen atom in the piperidine ring and readily forms salts 
with organic or inorganic acids. Fentanyl analogues (fentanils) have in common an aralkyl group 
attached to a 4-N-acylanilinopiperidine. 
4-Fluoroisobutyrylfentanyl is known from the scientific literature. 4-Fluoroisobutyrylfentanyl is the 
positional isomer of 4-fluorobutyrfentanyl (4F-BF) and thus both substances are structurally very 
closely related, which results in the same molecular formula and molecular mass. 
Pharmacologically, 4-fluoroisobutyrylfentanyl is an opioid receptor agonist. 
Synthetic opioids like fentanyl and related 4-anilinopiperidine derivatives are potent analgesics. 
Initially developed in the 1960’s as part of research efforts to develop safer and better opioid 
analgesics, a small number of this family of compounds—alfentanil, fentanyl, sufentanil and 
remifentanil—have become widely used in human medicine as adjuncts to general anaesthesia 
during surgery and for pain management. They are available in a wide variety of formulations, such as 
liquids for injection, tablets, transdermal patches, lozenges, and nasal sprays. Some are also used in 
veterinary medicine as general anaesthetics, for pain management, and, in the case of carfentanil and 
thiofentanil, to immobilise large animals.  
Fentanyl analogues first emerged on the illicit drug market in the United States of America in 1979. At 
the time they were not controlled under drug legislation. They were manufactured in clandestine 
laboratories and sold on the heroin market as heroin or ‘synthetic heroin’.  
A total of fifteen fentanils are controlled under the United Nations Single Convention on Narcotic 
Drugs, 1961, as amended by the 1972 Protocol. 
The major pharmacological effects of the fentanils, including their analgesic activity, are due to their 
activation of opioid receptors, and, in particular, the µ-opioid receptor. Besides their analgesic 
properties, a notable feature associated with µ-opioid receptor agonists is that they cause dose-
dependent respiratory depression, which in overdose can be life-threatening. Other additional 
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pharmacological effects include miosis, sedation, bradycardia, hypothermia, constipation, physical 
dependence, and changes in mood such as euphoria. 
4-Fluoroisobutyrylfentanyl as free base or as its hydrochloride salt may occur as solids. Due to its 
similarity to fentanyl, the free base could be expected to be sparingly soluble in water; the 
hydrochloride and citrate salt could be expected to have greater aqueous solubility; and the free base 
is expected to be lipophilic.  
In Europe, 4-fluoroisobutyrylfentanyl has been seized as a powder, tablet and as a liquid. It has been 
offered online as ready to use nasal sprays. 
The analytical identification of 4-fluoroisobutyrylfentanyl in physical and biological samples is possible 
using several analytical techniques. These include chromatographic and mass-spectrometric 
techniques. Routine commercially available immunoassays may not detect this compound. 
Analytical reference materials are important for the correct identification and for facilitating the 
quantification of 4-fluoroisobutyrylfentanyl in physical and biological samples. Such reference 
materials are commercially available. It should be noted that concentrations in blood samples can be 
in the sub-nanogram per millilitre range.  
As 4-fluoroisobutyrylfentanyl has only been on the drug market for a short period of time it may not be 
part of most drug screenings and therefore may be under-detected and under-reported. 
Route of administration and dosage 
As with other fentanils, 4-fluoroisobutyrylfentanyl can be administered orally as a powder (including in 
capsules), as tablets, or as a solution (using nasal sprays), or by insufflation of a powder; it can also 
be administered intranasally or sublingually via a spray; inhaled by smoking or vaporizing; and, 
administered by injection (intravenous and intramuscular). There are also instances where 4-
fluoroisobutyrylfentanyl is advertised for sale in the form of blotters by Internet vendors. Users have 
also described rectal administrations. 
From the limited data available it is not possible to discern the ‘typical’ dosages administered by 
users. While a range of doses have been reported, these appear to differ depending on factors such 
as the route of administration, the tolerance of the users, the use of other drugs, and the desired 
effects. 
Pharmacology 
Currently available data on the pharmacodynamics of 4-fluoroisobutyrylfentanyl are limited to studies 
investigating its binding and functional activity at opioid receptors in vitro, and its analgesic properties 
in mice. The in vitro data show that 4-fluoroisobutyrylfentanyl is a highly selective μ-opioid receptor 
agonist and that it is several times less potent than morphine and fentanyl. When the agonist activity 
of 4-fluoroisobutyrylfentanyl is compared with that of morphine, its potency over morphine is higher in 
tests in vivo (analgesia) than in tests in vitro (e.g., binding affinity for μ receptors). Its analgesic 
potency is almost ten times of that reported for morphine. 
The pharmacokinetic properties of 4-fluoroisobutyrylfentanyl are consistent with the high lipophilicity 
of fentanyl derivatives that results in rapid absorption and tissue distribution, including diffusion across 
the blood-brain barrier. 
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Recent studies indicate the metabolic pathway of 4-fluoroisobutyrylfentanyl shares some similarities 
with other fentanils. Consequently drug-drug interactions observed with fentanyl might equally apply.  
The concomitant use of other central nervous system (CNS) depressants, including other opioids, 
sedatives/hypnotics, ethanol, pregabalin, gabapentin, tranquillisers, and sedating anti-histamines, 
may produce additive depressant effects. 
Psychological and behavioural effects 
From the available data, the psychological and behavioural effects of 4-fluoroisobutyrylfentanyl may 
share some similarities with fentanyl and other opioid analgesics. These would include relaxation and 
euphoria; at higher doses, sedation and profound intoxication may occur. 
Legitimate uses 
4-Fluoroisobutyrylfentanyl is used as an analytical reference material in clinical and forensic case 
work/investigations as well as scientific research. There is currently no information that suggests 4-
fluoroisobutyrylfentanyl is used for other legitimate purposes. 
There are no reported uses of 4-fluoroisobutyrylfentanyl as a component in industrial, cosmetic, or 
agricultural products. In addition, a search of the Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) registered substances database hosted by the European 
Chemicals Agency (ECHA) using the available CAS Registry Numbers returned no hits. 
There is no marketing authorisation (existing, on-going, or suspended) for 4-fluoroisobutyrylfentanyl in 
the European Union or in the Member States that responded to the request for information that was 
undertaken as part of the Joint Report process (6). 
There is no information to suggest that 4-fluoroisobutyrylfentanyl is currently used in the manufacture 
of a medicinal product in the European Union (6). However, in the absence of a database on the 
synthetic routes of all medicinal products it is not possible to confirm whether or not 4-
fluoroisobutyrylfentanyl is currently used in the manufacture of a medicinal product. 
Chemical precursors that are used for the manufacture 
Information on the chemical precursors and the synthetic methods employed for 4-
fluoroisobutyrylfentanyl detected on the drug market within the European Union is limited.  
The manufacture of 4-fluoroisobutyrylfentanyl most likely relies on precursors and synthetic methods 
similar to those used for the manufacture of pharmaceutical fentanyl. Accordingly, methods developed 
for the synthesis of fentanyl are applicable to 4-fluoroisobutyrylfentanyl. Most of these are 
straightforward, make use of common laboratory equipment and precursors, and require only basic 
knowledge of chemistry. The substances N-(4-fluorophenyl)-1-(2-phenylethyl)piperidin-4-amine and 
isobutyryl chloride and/or isobutyric anhydride could be used for the manufacture of the substance. A 
potentially detectable impurity might be predicted to include N-(4-fluorophenyl)-1-(2-
phenylethyl)piperidin-4-amine. Use of a different acylating agent in the final acylation step could 
provide other fentanils. 
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A potential pre-precursor for 4-fluoroisobutyrylfentanyl and other fentanils, N-phenethyl-4-piperidone 
(NPP), has been recently scheduled (7). 
4-Fluoroisobutyrylfentanyl poses a risk of poisoning if accidental exposure occurs during its 
manufacture. Extreme care must be taken when carrying out the final synthetic step as well as when 
purifying and handling the substance. 
Health risks 
Individual health risks 
The assessment of individual health risks includes consideration of the acute and chronic toxicity of 4-
fluoroisobutyrylfentanyl, as well as its dependence potential, and its similarities to and differences 
from other chemically or pharmacologically related substances. 
It is important to note that when interpreting the information from deaths reported to the EMCDDA as 
well as information from user websites, that individuals may have used other substances in addition to 
4-fluoroisobutyrylfentanyl. The presence of and/or interaction with other substances or pre-existing 
health conditions may account for some of the reported effects. 
While specific information for 4-fluoroisobutyrylfentanyl is limited, of note is the apparent popularity of 
selling ready-to-use or using homemade nasal sprays containing solutions for the administration of 
fentanils. These typically contain milligram amounts of dissolved substance. The preparation of such 
solutions is inherently prone to mistakes in weighing and dilution which may lead to solutions with 
higher (or lower) concentrations. This may constitute an increased risk of acute toxicity to the 
individuals, who are unlikely to be able to control the dose of fentanil being consumed. 
In addition, recent seizures in Europe of nasal sprays containing other fentanils found that these have 
been sold in some cases as unlabelled bottles. In other cases, users have also filled nasal sprays 
previously containing medicines (such as nasal decongestants) with fentanils. The lack of labelling 
increases the potential for accidental use by others and therefore poses a risk of poisoning. 
4-Fluoroisobutyrylfentanyl may be used in combination with other drugs (intentionally or 
unintentionally).  
Limited data from seizures and collected samples have shown that 4-fluoroisobutyrylfentanyl has 
been detected in mixtures containing other opioids such as heroin and furanylfentanyl. The overall 
significance of these seizures is unclear; however, the identification of heroin in the seizures suggests 
that 4-fluoroisobutyrylfentanyl is being supplied through the illicit heroin market. 
Acute toxicity 
The acute toxicity of 4-fluoroisobutyrylfentanyl and/or its metabolites has not been studied in non-
clinical and clinical studies. 
Although the pharmacology and toxicology of 4-fluoroisobutyrylfentanyl largely remains unstudied, the 
available data suggests that the nature of its effects share some similarities with opioid analgesics 
                                                          
(7) Table I of the United Nations Convention against Traffic in Narcotic Drugs and Psychotropic Substances, 1988  
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such as morphine and fentanyl. The acute effects of these types of opioids include: euphoria, 
relaxation, analgesia, sedation, bradycardia, hypothermia, and respiratory depression. They also have 
an abuse liability and dependence potential. 
While there is limited data on the clinical features of poisoning caused by 4-fluoroisobutyrylfentanyl, 
features of poisoning are likely to include reduced level of consciousness or unconsciousness, 
respiratory depression and arrest, and miosis. Similar to other opioid analgesics, the most serious 
acute risk arising from the use of 4-fluoroisobutyrylfentanyl is probably respiratory depression, which 
can lead to apnoea, respiratory arrest, and death. 
The timely administration of the antidote naloxone should reverse acute poisoning caused by 4-
fluoroisobutyrylfentanyl. Recent clinical and community experience in treating poisonings caused by 
fentanils suggests that larger than normal doses and repeated doses of naloxone may be required to 
manage the poisoning in some cases; longer periods of observation may also be required. 
In general for fentanils, the risk of life-threatening poisoning may be exacerbated by: the difficulty in 
diluting/using fentanils (as they are typically highly potent), which can lead to a toxic dose being 
accidentally used; the apparent rapid onset of severe poisoning following use; using routes of 
administration that allow large amounts of the substance to rapidly reach the central nervous system 
(such as injecting, insufflation, and inhalation); availability of easy to use dosage forms (such as nasal 
sprays and e-liquids); lack of awareness and experience of users with these new substances (effects 
and dosage); use of other central nervous system depressants (such as other opioids, 
benzodiazepines, and alcohol); lack of tolerance to opioids in opioid-naïve persons (such as new or 
former users); use in environments where it may be difficult to summon help in the event of poisoning 
(e.g. alone in a home environment); and, limited availability of the antidote naloxone in community 
settings. 
In addition, and, often unknown to users, fentanils are sold as heroin or mixed with heroin. They are 
also used to make counterfeits of highly sought-after analgesics and benzodiazepines. They have 
also been sold in or as drugs such as cocaine. Due to this, users may not be aware that they are 
using a fentanil; in some cases these individuals will have no tolerance to opioids nor access to 
community naloxone programmes. Overall, these factors may increase the risk of life-threatening 
poisoning. 
Acute intoxications 
No acute intoxications with confirmed exposure to 4-fluoroisobutyrylfentanyl were reported to the 
EMCDDA.  
Deaths 
A total of 20 deaths were reported by 2 Member States: Sweden (16) and the United Kingdom (4). 
Exposure to 4-fluoroisobutyrylfentanyl was analytically confirmed in post-mortem samples in all cases 
from Sweden; no reference standard was available to distinguish between 4-fluoroisobutyrylfentanyl 
and 4-fluorobutyrylfentanyl in cases from the United Kingdom.  
The deaths occurred between July 2016 and March 2017, with 17 occurring in 2016 and 3 in 2017. Of 
the 18 deaths where demographic data were available, 16 were male (80%) and 2 were female 
(20%). The mean age of the males was 35 years (median 34) and ranged from 20 to 52 years; the 
age of the females was 24 and 36 years.  
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Cause of death and toxicological significance 
The cause of death was reported in 16 out of 20 cases. In at least 13 deaths, intoxication with 4-
fluoroisobutyrylfentanyl was reported either as the cause of death or as likely to have contributed to 
death (even in presence of other substances); other substances were detected in 19 cases. 
Post-mortem femoral blood concentrations of 4-fluoroisobutyrylfentanyl were quantified in 15 cases, 
and ranged from 0.76 to 370 ng/g blood (median 44 ng/g blood). In 2 cases, although the 
concentration was measured (44 and 85 ng/mL), it was not possible to determine if it related to 4-
fluoroisobutyrylfentanyl or 4-fluorobutyrylfentanyl. For a number of reasons, including variability in 
user tolerance, determination of a ‘fatal’ concentration based on a post-mortem blood concentration is 
not reliable. In the majority of circumstances involving fentanils, the mere presence of the drug is of 
significance whether concentration has been determined or not, especially in situations of poly-drug 
use. 
A range of other substances were detected in the deaths, including: cannabinoids, benzodiazepines, 
amphetamine, zopiclone, zolpidem, pregabalin, gabapentin, antidepressants, antipsychotics, 
antihistamines, a synthetic cathinone (alpha-PHP), ketamine, and ethanol (alcohol). Other 
opiates/opioids were detected in 9 of the deaths: codeine, buprenorphine, tramadol, methadone, 
oxycodone, fentanyl, despropionylfentanyl, tetrahydrofuranylfentanyl, and acryloylfentanyl. 
Overall, whilst other substances may have contributed some toxicity, a synergistic effect with 4-
fluoroisobutyrylfentanyl would have been likely with other central nervous system depressants such 
as ethanol, benzodiazepines, opioids, etc. Nevertheless, the potent opioid nature of 4-
fluoroisobutyrylfentanyl means that the primary toxic contribution could be attributed to 4-
fluoroisobutyrylfentanyl and death may not have occurred if 4-fluoroisobutyrylfentanyl had not been 
used. An assessment of the toxicological significance score (TSS) (8) incorporating the above 
considerations shows that 4-fluoroisobutyrylfentanyl had a TSS value of 3 (high) in 15 out of 16 of the 
deaths (where it was cited as the cause of death or is likely to have contributed to death). In the 
remaining death, an alternative cause of death (drowning) was cited (TSS value of 1, low). The 4 
cases where 4-fluoroisobutyrylfentanyl could not be unequivocally confirmed were not part of the 
assessment. 
Circumstances of death 
In the majority of cases there was a lack of information regarding any symptoms experienced by the 
deceased prior to death, but, where described in a few cases, the deceased had become 
unconscious and in one case the deceased was found convulsing. Where information was known, in 
the majority of instances the individuals were found dead, predominantly in a home environment 
(either their own or a friend’s). Consequently, it was not possible to identify or evaluate ante-mortem 
symptoms (especially in relation to acute intoxication) in these cases. 
Deaths from other sources 
In addition to deaths reported by the EMCDDA, more than 60 deaths with confirmed exposure to 4-
fluoroisobutyrylfentanyl have recently been reported in the United States. 
 
                                                          
(8) Elliott, S., Sedefov, R. and Evans-Brown, M. (2017), 'Assessing the toxicological significance of new psychoactive 
substances in fatalities', Drug Testing and Analysis. https://doi.org/10.1002/dta.2225 
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Ability to operate machinery and drive 
There have been no studies of the effects of 4-fluoroisobutyrylfentanyl on the ability to drive and 
operate machines. However, it is well established that opioid narcotic analgesics, such as fentanyl, 
impair the mental and physical ability required to drive and operate machines. This effect is likely to 
extend to 4-fluoroisobutyrylfentanyl. 
Chronic toxicity 
No studies were identified that investigated the chronic health effects of 4-fluoroisobutyrylfentanyl 
and/or its metabolites. 
Abuse liability and dependence potential 
There have been no studies that have investigated the abuse liability and dependence potential of 4-
fluoroisobutyrylfentanyl. Given what is currently known about its pharmacology, including some 
similarities to other fentanils and opioid narcotic analgesics, it may have a potential for abuse and 
dependence. Further research will be required in order to determine such effects. 
Public health risks 
The public health risks associated with 4-fluoroisobutyrylfentanyl may be categorised in terms of 
patterns of use (extent, frequency, route of administration, etc.); availability and quality of the drug; 
information, availability and levels of knowledge amongst users; and, negative health consequences. 
Detailed information, including data on sporadic versus chronic use, that allow for a determination of 
public health risks associated with 4-fluoroisobutyrylfentanyl are not available. In addition, risk of 
accidental exposure needs to be considered.  
Extent, frequency, and patterns of use 
No studies were identified that have investigated the prevalence of use of 4-fluoroisobutyrylfentanyl in 
the general population. Given its pharmacology and that it is sold openly as a ‘legal’ replacement to 
illicit opioids, it would be expected that users looking for substitutes for opioids, which would include 
individuals who use illicit opioids, such as heroin and/or prescription opioids, may seek out 4-
fluoroisobutyrylfentanyl and other fentanils. It also appears that there is interest in this substance by 
some psychonauts. Overall, the available information does not suggest widespread use of the 
substance. 
4-Fluoroisobutyrylfentanyl appears to be sold online in small and wholesale amounts as powders, 
liquids, and blotters (sometimes as a ‘research chemical’). 4-Fluoroisobutyrylfentanyl may also be 
sold on the illicit opioid market, as suggested by seizures where it was found in mixtures with other 
opioids such as heroin and furanylfentanyl. In these cases, it is reasonable to assume that these 
individuals will not be aware that they are consuming 4-fluoroisobutyrylfentanyl. 
Availability and quality on the market 
A total of 24 seizures have been reported by 4 Member States. The majority of the seizures took 
place in 2016, with a smaller number reported in 2017. 4-Fluoroisobutyrylfentanyl has been typically 
seized as a powder (9 seizures; total of 378.6 g), in tablet form (12 seizures; 6727 tablets), and as a 
liquid (3 seizures; total of 208 ml).  
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It is important to note that detections of 4-fluoroisobutyrylfentanyl may be under-reported since the 
substance is not routinely screened for. 
Powders, liquids, and blotters claiming to contain 4-fluoroisobutyrylfentanyl have been offered by 
online vendors apparently based within the European Union.  
The availability of 4-fluoroisobutyrylfentanyl on the darknet is not currently known.  
Characteristics and behaviour of users 
While no specific examples are available on the possible appeal of 4-fluoroisobutyrylfentanyl to user 
groups (aside from psychonauts), it is reasonable to assume that the substance may be sought by 
those looking for ‘legal’ substitutes for illicit opioids (such as heroin) and/or prescription opioids.  
The available information, including deaths reported by the Member States, suggests that 4-
fluoroisobutyrylfentanyl is used in the home environment. In the majority of the deaths the individuals 
were found dead, often in a home environment. It appears that in at least some of these cases the 
poisoning with of 4-fluoroisobutyrylfentanyl was so severe that they were unable to call for help. 
Polydrug use, including the use of other central nervous system depressants such as opioids, was 
common in the deaths. 
Nature and extent of health consequences 
In addition to the individual health risks that are discussed above, there are some further 
considerations related to the fentanils as a group that should be considered in respect to potential 
risks to public health. 
Mirroring the increased availability of fentanils on the drug market over the past few years, there has 
also been an increase in the number of outbreaks of mass poisoning caused by fentanils, particularly 
in the United States and Canada. These types of outbreaks have had the potential to overwhelm 
emergency responders and other local healthcare systems, as well as deplete stocks of naloxone. 
Stocks and availability of the naloxone, as well as adequacy of training in how to resuscitate poisoned 
patients both in clinical and community settings may need to be assessed. This might also include a 
review of the availability of naloxone to users through take-home naloxone programmes. 
As noted, new dosage forms—such as ready-to-use nasal sprays and e-liquids for vaping—along with 
open sales on the surface web and darknet marketplaces add to the complexity of the problem 
caused by the fentanils. They have become easier to get hold of and easier to use. The Committee is 
concerned about whether the availability of ‘novel’ dosage forms has the potential to make the use of 
fentanils more socially acceptable. 
An additional challenge in respect to reducing risk in users and potential users is the balance between 
providing information to prevent harm and the unintended consequences of communicating the risks 
of opioids. There is evidence that using terms to describe them as 'potent', 'strong', 'deadly', and 'toxic' 
can lead some individuals to specifically seek out these substances. Such unintended promotion of 
the substances may also extend to former users and other groups. 
Adding to these challenges is evidence from Europe, the United States, and Canada that fentanils are 
being sold to unsuspecting users in/as heroin, counterfeit medicines (including commonly used opioid 
analgesics and benzodiazepines), cocaine, and other illicit drugs. As users will be unaware of this, it 
increases the risk of severe and fatal poisoning in both opioid users and especially other groups who 
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may have no existing tolerance to opioids. Non-opioid users are unlikely to be aware of these risks 
and are unlikely to have access to community opioid overdose prevention programmes, including 
take-home naloxone programmes. 
Accidental exposure to fentanils may also pose a risk of poisoning to those who may come into 
contact with the substances. This includes the family and friends of users, law enforcement, 
emergency personnel, medical and forensic laboratory personnel, as well as those in custodial 
settings and postal services. Where necessary, specific risks should be identified and assessed, and, 
appropriate measures to reduce these risks should be implemented. This may include appropriate 
protective equipment, training in resuscitation, and making naloxone readily available to relevant 
personnel in sufficient quantities in the event of poisonings. Any required measures should continue 
to ensure the delivery of prompt and appropriate care to patients with suspected overdose. 
Long-term consequences of use 
There is no information on the long-term consequences of use of 4-fluoroisobutyrylfentanyl. 
Conditions under which the substance is obtained and used 
There is limited information on the conditions which 4-fluoroisobutyrylfentanyl is obtained and used. 
The substance is offered for sale on the surface web as a powder, liquids, and blotters. 
4-Fluoroisobutyrylfentanyl has also been seized as tablets.  
Information from a seizure case in the United Kingdom suggests that 4-fluoroisobutyrylfentanyl has 
been sold on the illicit opioid market in mixtures with heroin. 
Overall, 4-fluoroisobutyrylfentanyl may be deliberately sought after by some users; others, such as 
those that purchase it at street-level, may be unaware that they are using the substance which 
presents an inherent risk to the individuals. 
Social risks  
While there have been no studies on the social risks of 4-fluoroisobutyrylfentanyl, it is likely that some 
of the risks are similar to those seen with opioids such as fentanyl and heroin. 
Individual social risks 
There is no information on whether the use of 4-fluoroisobutyrylfentanyl causes individual social risks; 
however, any such risks may have some similarities with those associated with the use of illicit 
opioids, including fentanyl. These may impact on education or career, family or other personal and 
social relationships and may result in marginalisation. 
Possible effects on direct social environment (e.g. neglect of family, violence) 
There is no information on the possible effects of 4-fluoroisobutyrylfentanyl on the direct social 
environment; however, any such risks may have some similarities with those associated with the use 
of illicit opioids.  
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Possible effects on society as a whole (public order and safety, acquisitive crime) 
There is no specific information on the possible effects of 4-fluoroisobutyrylfentanyl on society as a 
whole.  
As discussed above, accidental exposure of fentanils may pose a risk of poisoning to those who may 
come into contact with the substances. This includes the family and friends of users, law enforcement, 
emergency personnel, medical and forensic laboratory personnel, as well as those in custodial 
settings and postal services. 
Economic costs  
There are no data on the effects of 4-fluoroisobutyrylfentanyl in respect to its health and social costs. 
Possible appeal to specific population groups 
Whilst no specific examples are available on the possible appeal of 4-fluoroisobutyrylfentanyl to user 
groups, it is reasonable to assume that the substance may be sought by those looking for substitutes 
for illicit opioids, such as heroin and/or prescription opioids.  
As highlighted, concerns exist over the use of fentanils with novel dosage forms—such as ready-to-
use and homemade nasal sprays and e-liquids for vaping—which have the potential to make the use 
of these substances easier (with similar effects to injecting) and more socially acceptable. Further 
research is required on this topic to better understand the risks. 
Information on manufacturing, trafficking, distribution, and the level of 
involvement of organised crime  
There is no information to suggest the involvement of organised crime or established criminal groups 
in the manufacture, distribution, and supply of 4-fluoroisobutyrylfentanyl.  
Slovenia reported a collected sample of 4-fluoroisobutyrylfentanyl to both Europol and the EMCDDA 
where the country of origin was indicated as China. Belgium reported a seizure of 4-
fluoroisobutyrylfentanyl to the EMCCDA where the final destination was Germany. 
The seizure of an illicit laboratory producing fentanils in Europe in 2013 suggests that the capability to 
manufacture fentanils may exist within the European Union. 
Information on any assessment in the United Nations system 
The World Health Organization (WHO) is the specialised United Nations agency designated for the 
evaluation of the medical, scientific and public health aspects of psychoactive substances under the 
Single Convention on Narcotic Drugs, 1961, and the Convention on Psychotropic Substances, 1971. 
In May 2017, the WHO informed the EMCDDA that 4-fluoroisobutyrylfentanyl will be reviewed at the 
39th meeting of the WHO Expert Committee on Drug Dependence (ECDD) that will be held in 
November 2017. 
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Description of the control measures that are applicable in the Member 
States 
Seven Member States (Cyprus, Estonia, France, Latvia, Lithuania, Sweden, and the United Kingdom) 
reported that 4-fluoroisobutyrylfentanyl is controlled under drug control legislation. 
 In Cyprus, 4-fluoroisobutyrylfentanyl is controlled as a Class A drug within the Narcotic Drugs 
and Psychotropic Substances Law 1977.  
 In Estonia 4-fluoroisobutyrylfentanyl is controlled by way of generic definition.  
 In France, 4-fluoroisobutyrylfentanyl is controlled as of 5 September 2017. 
 In Latvia, 4-fluoroisobutyrylfentanyl is included in the Cabinet Regulation N 847 ‘Regulations 
regarding Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in 
Latvia’ and the law ‘On the Procedures for the Coming into force and Application of the 
Criminal Law’.  
 In Lithuania, 4-fluoroisobutyrylfentanyl is subjected to control measures by The Republic of 
Lithuania Minister of Health Order No V-22 (06/01/2017) ‘On the amendment of the Ministry of 
Health of the Republic of Lithuania Order No. 5 of 6 January 2000’. 
 In Sweden, 4-fluoroisobutyrylfentanyl is regulated under the Act on the Prohibition of Certain 
Goods Dangerous to Health, as of 25 January 2017. 
 In the United Kingdom, 4-fluoroisobutyrylfentanyl is controlled under the Misuse of Drugs Act 
1971 by way of a generic definition.  
Three Member States (Austria, Belgium, and Poland) reported that 4-fluoroisobutyrylfentanyl is 
controlled under specific new psychoactive substances control legislation.  
 In Austria, 4-fluoroisobutyrylfentanyl is covered by the phenethylamine generic definition 
within the Austrian Act on New Psychoactive substances.  
 In Belgium, 4-fluoroisobutyrylfentanyl is controlled by way of generic definition.  
 In Poland, 4-fluoroisobutyrylfentanyl is controlled according to the general definition of the 
‘substitute drug’ (Act of 8 October 2010 amending the Act on counteracting drug addiction 
and the Act on State Sanitary Inspection, Journal of Laws “Dz.U.” No. 213, item 1396). 
Pursuant to Article 44b of the Act on counteracting drug addiction, it is prohibited to 
manufacture and introduce substitute drugs to trade.  
Seventeen Member States (Bulgaria, Croatia, Czech Republic, Denmark, Finland, Germany (9), 
Greece, Hungary (9), Ireland, Italy, Luxembourg, Malta, the Netherlands, Portugal, Romania, 
Slovenia, and Spain), Turkey and Norway reported that 4-fluoroisobutyrylfentanyl is not subject to 
control measures at the national level. 
Slovakia did not provide information on the control status of 4-fluoroisobutyrylfentanyl. 
                                                          
(9) As part of the Joint Report process, it was reported by the German and Hungarian national focal points that 4-
fluoroisobutyrylfentanyl is not controlled in Germany and Hungary, respectively (6). However, during the risk 
assessment meeting, two experts who were present informed that the substance is controlled under specific new 
psychoactive substances control legislation, by way of generic definition. As such, the control of the substance has 
been reflected in the totals that are presented in the conclusion. 
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Options for control and the possible consequences of the control 
measures 
Under Article 9.1 of the Council Decision, the option for control that is available at European Union 
level is for the Member States to submit the new psychoactive substance 4-fluoroisobutyrylfentanyl to 
control measures and criminal penalties, as provided for under their legislation, by virtue of their 
obligations under the Single Convention on Narcotic Drugs, 1961.  
There are no studies on the possible consequences of such control measures on 4-
fluoroisobutyrylfentanyl. If this option of control is pursued, the Committee considers that the following 
consequences are possible. Some of these may apply to any new psychoactive substance. 
 This control option could be expected to limit the availability of 4-fluoroisobutyrylfentanyl and 
hence the further expansion of the current open trade in this substance. 
 A health consequence that might result from this control option is the benefit brought about by 
the presumed reduction in availability and use.  
 This control option could facilitate the detection, seizure and monitoring of 4-
fluoroisobutyrylfentanyl related to its unlawful manufacture, trafficking and use. In so doing, it 
could facilitate cooperation between the judicial authorities and law enforcement agencies 
across the European Union. 
 This control option would imply additional costs for the criminal justice system, including 
forensic services, law enforcement, and the courts. 
 This control option could lead to replacement with other (established or new) psychoactive 
substances, which may in themselves have public health consequences and social risks.  
 This control option could create an illicit market in 4-fluoroisobutyrylfentanyl with the 
increased risk of associated criminal activity, including the involvement of organised crime. 
 This control option could impact on both the quality/purity and price of any 4-
fluoroisobutyrylfentanyl still available on the illicit market. The extent to which this will impact 
on public health, criminality, or levels of use, is difficult to predict. 
 It is difficult to predict the impact of this control option on current or future research by the 
pharmaceutical or chemical industries. 
 In order to examine the consequences of control, the Committee wishes to note that it will be 
important to monitor for the presence of 4-fluoroisobutyrylfentanyl on the market post-control, 
should this control option be pursued. 
 Aside from the option for control under those stipulated in Article 9.1 of the Council Decision, 
other options for control may be available to Member States. These may include restricting 
the importation and supply of the substance as some Member States have already done.  
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Conclusion 
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4-
fluoroisobutyrylfentanyl) is a synthetic opioid and is structurally related to fentanyl, a controlled 
substance widely used in medicine as an adjunct to general anaesthesia during surgery and for pain 
management. Currently available information suggests that 4-fluoroisobutyrylfentanyl is a narcotic 
opioid analgesic similar to fentanyl. 
Similar to other opioid analgesics, the most serious acute risk arising from the use of 4-
fluoroisobutyrylfentanyl is probably from respiratory depression, which can lead to apnoea, respiratory 
arrest, and death.  
4-Fluoroisobutyrylfentanyl has been available in Europe since at least August 2016 and has been 
seized in 4 Member States. Sixteen deaths have been reported by 1 Member State where exposure 
to 4-fluoroisobutyrylfentanyl was confirmed. In many of cases, other drugs were also detected with 4-
fluoroisobutyrylfentanyl. In at least 13 of the deaths, 4-fluoroisobutyrylfentanyl was reported to be 
either the cause of death or to have contributed to death. There have also been reports of deaths 
from the United States with confirmed exposure to the substance. 
It is likely that naloxone works as an antidote to poisoning caused by 4-fluoroisobutyrylfentanyl. 
It is important to note that detections of 4-fluoroisobutyrylfentanyl may be under-reported since the 
substance is not routinely screened for. Routine commercially available immunoassays may not 
detect this compound. 
4-Fluoroisobutyrylfentanyl is sold online as a ‘research chemical’, typically as a powder and as ready-
to-use nasal sprays, in small and wholesale amounts. Limited information from seizures suggests that 
4-fluoroisobutyrylfentanyl may have also been sold on the illicit opioid market. 
The substance can be administered by nasal spray, by nasal insufflation and orally. Other routes of 
administration, including injecting, and vaping of e-liquids have also been reported for fentanils. 
Particular concerns exist over novel ways of administering fentanils including 4-
fluoroisobutyrylfentanyl. These include nasal sprays and e-liquids for vaping. These may have the 
potential to make the use of fentanils easier and more socially acceptable.  
Information from police seizures as well as investigations into deaths indicates that 4-
fluoroisobutyrylfentanyl is available to and being used by high-risk drug users, including opioid users. 
Accidental exposure to 4-fluoroisobutyrylfentanyl, as well as to other fentanils, may pose a risk to law 
enforcement, emergency personnel, medical and forensic laboratory personnel, as well as to those in 
custodial settings and postal services. Where necessary, specific risks and appropriate measures to 
reduce these risks should be identified and implemented. Any required measures should continue to 
ensure the delivery of prompt and appropriate care to patients with suspected overdose. 
There is no information regarding the involvement of organised crime in the manufacture, distribution 
(trafficking) and supply within the European Union. However, given the fact that it has been detected 
in heroin samples the involvement of organised crime cannot be excluded. There is limited 
information on the chemical precursors and the synthetic routes used to manufacture the 4-
fluoroisobutyrylfentanyl detected within the European Union. Most of the synthetic routes are 
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straightforward, make use of common laboratory equipment and readily available precursors, and 
require only basic knowledge of chemistry.  
Information from seizures suggests that some 4-fluoroisobutyrylfentanyl on the market in Europe has 
been produced by chemical companies based in China.  
4-Fluoroisobutyrylfentanyl has no recognised human or veterinary medical use in the European 
Union, nor, it appears, elsewhere. There are no indications that 4-fluoroisobutyrylfentanyl may be 
used for any other purpose aside from as an analytical reference standard and in scientific research. 
4-Fluoroisobutyrylfentanyl is not listed for control in the Single Convention on Narcotic Drugs, 1961, 
nor in the Convention on Psychotropic Substances, 1971. 4-Fluoroisobutyrylfentanyl is currently 
under assessment by the United Nations system.  
Seven Member States control 4-fluoroisobutyrylfentanyl under drug control legislation. Five Member 
States control 4-fluoroisobutyrylfentanyl under other legislation. 
As for any new psychoactive substance, many of the questions related to 4-fluoroisobutyrylfentanyl 
that are posed by the lack of data on the risks to individual health, risks to public health, and social 
risks, could be answered through further research. Areas where additional information would be 
important include studies on: rationale for use, prevalence and patterns of use (including studies that 
examine user groups and risk behaviours); the market; chemical profiling; complete pharmacological 
profiling; metabolic pathways; behavioural effects; acute and chronic toxicity; the potential interaction 
between 4-fluoroisobutyrylfentanyl and other substances; the dependence and abuse potential; and 
the public health risks associated with its use. 
The Committee notes that a decision to control 4-fluoroisobutyrylfentanyl has the potential to bring 
with it both intended and unintended consequences. Potential intended consequences include 
reduced levels of availability and ultimately use. This may reduce the health and social risks and 
consequences arising from the use of 4-fluoroisobutyrylfentanyl. It is important to recognise that a 
potential unintended consequence of control may be the manufacture and availability of other 
substances. Indeed, since 4-fluoroisobutyrylfentanyl was first detected at least nine new fentanils and 
a number of other new opioids that may replace it are already being sold on the drug market. The 
implementation of control measures may also lead to the criminalisation of those who continue to use 
this substance with the possible attendant risks of socio-economic stigmatisation and marginalisation.  
Finally, the Committee notes that it is important to continue to collect and disseminate accurate 
information on 4-fluoroisobutyrylfentanyl to users, practitioners, policy makers, decision makers, and 
those who may be at risk of accidental exposure. An additional challenge in respect to reducing risk in 
users and potential users is the balance between providing information to prevent harm and the 
unintended consequences of communicating the risks of opioids. There is evidence that using terms 
to describe them as 'potent', 'strong', 'deadly', and 'toxic' can lead some individuals to specifically seek 
out these substances. Such unintended promotion of the substances may also extend to former users 
and other groups. 
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ANNEX 1 
Introduction 
In accordance with Article 5 of the Council Decision 2005/387/JHA on the information exchange, risk-
assessment and control of new psychoactive substances (1) on 25 April 2017, the EMCDDA and 
Europol launched the Joint Report procedure for N-(4-fluorophenyl)-2-methyl-N-[1-(2-
phenylethyl)piperidin-4-yl]propanamide (4-fluoroisobutyrylfentanyl) on the basis of data reported by 
the Member States to the European Union Early Warning System in accordance with Article 4 of the 
Council Decision. The information collection process for the Joint Report was completed in June 
2017. The report was submitted to the Institutions of the European Union in July 2017 (EMCDDA, 
2017a). In accordance with Article 6 of the Council Decision, on 14 September 2017, the Council of 
the European Union requested that a risk assessment on 4-fluoroisobutyrylfentanyl should be carried 
out by the extended Scientific Committee of the EMCDDA. 
In order to prepare for a risk assessment, and, to facilitate the risk assessment process, the EMCDDA 
is responsible for the collection and analysis of data on the substance to be assessed as well as 
drafting a technical report. This technical report has been prepared for the risk assessment of 4-
fluoroisobutyrylfentanyl that will be held at the EMCDDA premises in Lisbon on Wednesday 8 
November 2017. 
Some of the sections in this report were prepared under EMCDDA contracts (ref. CT.17.SAT.0084.1.0 
and CT.17.SAT.0110.1.0). 
Data sources 
The information in this technical report is derived from: 
 data reported by the Member States, Turkey, and Norway to the EMCDDA and Europol in 
accordance with the Council Decision (EMCDDA, 2017a); and,  
 data collected through systematic searches of open source information, including the 
scientific and medical literature, patents, official reports, grey literature, Internet drug 
discussion forums and related websites, and online vendors selling 4-fluoroisobutyrylfentanyl. 
Search strategy  
Literature searches used both chemical structure and text queries in online databases; searches were 
conducted in October 2017. The retrieved publications were then reviewed for additional relevant 
references (snowballing technique). 
Chemical structure-based searches were done in SciFinder® (American Chemical Society, Chemical 
Abstract Service) and Reaxys® (Elsevier) databases using both the exact structure of 4-
                                                          
(1) OJ L 127, 20.5.2005, p. 32.  
Technical report on N-(4-fluorophenyl)-2-methyl-N-
[1-(2-phenylethyl)piperidin-4-yl]propanamide  
(4-fluoroisobutyrylfentanyl; 4F-iBF) 
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fluoroisobutyrylfentanyl and a similarity search. Structural and text-based searches in the 
SureChEMBL patent database retrieved only one, though irrelevant, hit (2). 
Textual searches were conducted online in PubMed (National Center for Biotechnology Information), 
Web of Science™ (Thomson Reuters), and in popular English-language drug forums. The search 
terms used were: ‘4-fluoroisobutyrylfentanyl’, ‘4-fluoro-isobutyrylfentanyl’, ‘4-fluoro-isobutyrfentanyl’, 
‘4-fluoro-isobutrylfentanyl’, ‘para-fluoroisobutyrylfentanyl’, 4-F-iBF, 4-FiBF, 4-FIBF, FIBF, p-FIBF and 
p-FiBF. 
The REACH registered substances database hosted by the European Chemicals Agency (ECHA) 
was searched using the CAS registry numbers listed below. The searches returned no hits. 
Cursory, though repeated, inspections of English-language Internet forums covered Bluelight, Drugs-
forum, ecstasydata.org, Erowid, Eve&Rave, Reddit and The Vespiary. 
Additionally, the scientific networks of the authors were contacted to obtain information. 
Note 
It is important to note that when interpreting the information on self-reported user experiences in this 
report, it is not possible to confirm the specific substance(s) that have been claimed to be used; 
similarly it is also not possible to confirm the strength, purity, dose/amount, etc., used. Moreover, the 
actual composition of the substance/product may differ over time and different geographical areas. In 
addition, the information provided on user websites may not necessarily be representative of other 
users of 4F-iBF and should be regarded as illustrative only. In general, given the difficulties of 
collecting accurate self-reported data, it should be interpreted with caution. 
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Rita Jorge, Rachel Christie, Ana Gallegos, and Roumen Sedefov (5). 
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Section A. Physical, chemical, pharmaceutical and pharmacological 
information 
A1. Physical, chemical, and pharmaceutical information 
A1.1. Physical and chemical description 
Chemical description and names 
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4-
fluoroisobutyrylfentanyl) is structurally related to fentanyl, which is a fast and short-acting synthetic 
opioid that has been widely used in clinical practice as an adjunct to general anaesthesia during 
surgery and for postoperative pain management. 4-Fluoroisobutyrylfentanyl contains one basic 
nitrogen atom in the piperidine ring readily forming salts with organic or inorganic acids.  
4-Fluoroisobutyrylfentanyl is also structurally related to acetylfentanyl, acryloylfentanyl, and 
furanylfentanyl, which were the subjects of EMCDDA–Europol Joint Reports submitted in December 
2015, November 2016 and January 2017, respectively, following reports of deaths in Europe 
(EMCDDA, 2016a; EMCDDA, 2017b; EMCDDA, 2017c). In February 2017 and May 2017, risk 
assessment meetings on acryloylfentanyl (EMCDDA, 2017d) and furanylfentanyl (EMCDDA, 2017e) 
were convened under the auspices of the Scientific Committee of the EMCDDA following the request 
by the Council of the European Union. On 25 September 2017, the Council of the European Union 
decided that acryloylfentanyl should be subjected to control measures across the European Union 
(CEU, 2017). 
4-Fluoroisobutyrylfentanyl differs from fentanyl by the presence of a fluorine atom on the anilido 
phenyl ring and the presence of an isobutyramide group in place of the propanamide group. 4-
Fluoroisobutyrylfentanyl is the positional isomer of 4-fluorobutyrfentanyl (4F-BF) and thus both 
substances are structurally very closely related, which results in the same molecular formula and 
molecular mass. The molecular structure, molecular formula, and molecular mass of 4-
fluoroisobutyrylfentanyl are provided in Figure 1.  
The first reference to 4-fluoroisobutyrylfentanyl in the scientific literature appears to have been in a 
paper published in 1999, wherein the synthesis of the substance and analytical discrimination from 
fentanyl was reported (Ohta, 1999). 
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FIGURE 1 
The molecular structure, molecular formula and molecular mass of 4-fluoroisobutyrylfentanyl 
(left), 4-fluorobutyrylfentanyl (middle) and fentanyl (right). 
4-fluoroisobutyrylfentanyl 4-fluorobutyrylfentanyl Fentanyl 
   
C23H29FN2O C23H29FN2O C22H28N2O 
368.50 g/mol 368.50 g/mol 336.48 g/mol 
Fifteen fentanils are controlled under the United Nations Single Convention on Narcotic Drugs, 1961, 
as amended by the 1972 Protocol: 3-methylfentanyl, 3-methylthiofentanyl, acetyl-alpha-
methylfentanyl, acetylfentanyl, alpha-methylfentanyl, alpha-methylthiofentanyl, beta-hydroxy-3-
methylfentanyl, beta-hydroxyfentanyl, para-fluorofentanyl and thiofentanyl, are controlled under 
Schedule I and IV; alfentanil, butyrfentanyl, fentanyl, remifentanil and sufentanil are controlled under 
Schedule I. The controls on acetylfentanyl and butyrfentanyl entered into force in 2016 and 2017, 
respectively. 
Names and other identifiers 
Systematic International Union of Pure and Applied Chemistry (IUPAC) name: 
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide  
Chemical Abstract name:  
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide 
Other names:  
N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide; 
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide;  
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidyl]propanamide; 
N-(4-Fluorophenyl)-N-(1-phenethyl-4-piperidinyl)isobutyramide; 
N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide 
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Chemical Abstract Service Registry Numbers (CAS RNs) (6) 
244195-32-2. 
PubChem SID:  
Could not be identified (7). 
IUPAC International Chemical Identifier Key (InCHI Key)(8):  
OZDOSQNUJIXEOR-UHFFFAOYSA-N 
SMILES (9):CC(C)C(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=C(F)C=C3 
Common names:  
4-fluoroisobutyrylfentanyl, 4-fluoro-isobutyrylfentanyl, 4-fluoro-isobutyrfentanyl, para-
fluoroisobutyrylfentanyl, 4-F-iBF, 4-FiBF, 4-FIBF, FIBF, p-FIBF, p-FiBF. 
Street names:  
The street names for 4-fluoroisobutyrylfentanyl may include the common names. 
Identification and analytical profile 
Physical description  
4-Fluoroisobutyrylfentanyl hydrochloride has been described as a neat solid (Cayman Chemical 
Company, 2017) and as a white powder (base) (SWGDRUG, 2016). Due to its similarity to fentanyl, 
the free base could be expected to be sparingly soluble in water; the hydrochloride and citrate salt 
could be expected to have greater aqueous solubility. 4-Fluoroisobutyrylfentanyl is expected to be 
lipophilic. This substance has been seized as a powder, in tablet form, and as a liquid. A more 
detailed description of seizures and collected samples can be found in Section C. 
Chemical stability and typical reactions 
Specific information about 4-fluoroisobutyrylfentanyl could not be identified. For long-term storage it is 
recommended that 4-fluoroisobutyrylfentanyl, supplied as a solid, is stored at -20 °C (Cayman 
Chemical Company, 2017) 
Analytical profile 
As summarized in Table 1, some analytical data have been published.  
It is possible that immunoassays for fentanyl may not distinguish between 4-fluoroisobutyrylfentanyl 
and fentanyl due to the structural similarity between the two substances. Identification of 4-
fluoroisobutyrylfentanyl therefore would require further confirmatory analysis using more suitable 
                                                          
(6) The Chemical Abstract Service Registry Number (CAS RN) is a unique numeric identifier assigned by the Chemical Abstract 
Service Division of the American Chemical Society to a specific, single chemical substance. 
(7) As of 21.10.2017 
(8) InChI Key is a unique, non-proprietary structural identifier of chemical substances useful in electronic sources. 
(9) The simplified molecular-input line-entry system (SMILES) is a unique, non-proprietary structural identifier of chemical 
substances useful in electronic sources. 
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detection techniques based on, for example, (tandem) mass spectrometry (Helander et al., 2017). 
Similarly, 4-fluoroisobutyrylfentanyl is not expected to give a positive response to tests developed for 
morphine-type opioids. An analytical challenge might arise from the number of potential positional 
isomers that could exist as a result of the presence of the fluorine atom. For example, three 
fluorophenyl and three fluorophenylethyl isomers (2F-, 3F-, 4F-) can exist when just considering the 
two phenyl rings present in the molecule. These six isomers could also apply to the 4-
fluorobutyrylfentanyl counterparts, thus, potentially giving rise to twelve isomers. Information about the 
detection of isomers other than 4-fluoroisobutyrylfentanyl could not be identified. The availability of 
standard reference material is recommended in order to facilitate their differentiation. 
Analytical difficulty arises due to the isobaric nature and very similar fragmentation patters of 4-
fluoroisobutyrylfentanyl and 4-fluorobutyrylfentanyl. Forensic laboratories, being aware of this, often 
report results as ‘4-fluoroisobutyrylfentanyl/4-fluorobutyrylfentanyl’ for samples where the isobaric 
substances were not, or could not be, separated. 
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TABLE 1 
Information associated with the detection and chemical analysis of 4-fluoroisobutyrylfentanyl 
(amongst other substances). a   
Techniques b Comment  Reference 
TLC, GC-FID, direct inlet EI-MS, IR  Synthesis and analytical 
characterisation. 
Ohta et al. (1999) 
1H-NMR, GC-MS, FTIR-ATR 
  
Analytical characterisation of 
reference material. 
SWGDRUG (2016) 
GC-MS Analytical characterisation of 
reference material. 
Cayman Chemical Company 
(2017) 
GC-MS, LC-MS/MS Blood analysis of ‘overdose’ cases. DeRienz et al. (2017) 
LC-MS(/MS) Analysis of serum and urine sample 
obtained from an intoxication case 
in September 2016. 
Helander et al. (2017) 
LC-MS/MS Method validation and application to 
analysis of postmortem biological 
sample material. 
Kahl et al. (2017) 
GC-MS Retrospective analysis of GC-MS 
results obtained from blood 
samples. 
Newmeyer et al. (2017) 
GC-MS, GC-NPD Detection in blood sample. Poston et al. (2017) 
GC-MS, GC-FTIR (condensed 
phase)  
 
Analytical characterisation of 
reference material. 
Slovenian National Forensic 
Laboratory (2017) 
GC-MS Analysis of drug paraphernalia 
(spoon residue) found at the site of 
fatal intoxication.c  
Swanson et al. (2017) 
LC-MS/MS Analysis of postmortem and human 
performance toxicology casework 
Turri et al. (2017) 
LC-MS(/MS) In vitro metabolism using pooled 
human hepatocytes and analysis of 
authentic human urine samples. 
Watanabe et al. (2017) 
GC-MS, LC-MS Analysis of drug paraphernalia 
(spoon residue) and analysis of 
postmortem blood specimen.  
Zaney et al. (2017) 
a As of 21 October 2017. 
b TLC: Thin-layer chromatography; GC: gas chromatography; FID: flame ionization detection; EI: electron ionization; MS: mass 
spectrometry; IR: infrared spectroscopy; NMR: nuclear magnetic resonance spectroscopy; FT: Fourier transform; ATR: 
attenuated total reflectance; LC: liquid chromatography; MS/MS: tandem MS; NPD: nitrogen phosphorus detector;  
c Identification based on mass spectral library comparison only. 
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Methods and chemical precursors used for the manufacture  
No information was reported by the Member States, Turkey, or Norway, about the chemical 
precursors or manufacturing methods used to make the 4-fluoroisobutyrylfentanyl that has been 
detected within Europe.  
Synthesis 
A synthesis procedure for 4-fluoroisobutyrylfentanyl could not be identified in the published literature 
but it seems likely that its synthesis relies on precursors and synthetic methods similar to those used 
for the manufacture of pharmaceutical fentanyl and other fentanyl analogues. Accordingly, methods 
adapted for the multistep synthesis of fentanyl are applicable to 4-fluoroisobutyrylfentanyl whereby the 
final reaction step is expected to apply the acylation of the N-(4-fluorophenyl)-1-(2-
phenylethyl)piperidin-4-amine intermediate, a precursor analogous to the N-phenyl-1-(2-
phenylethyl)piperidin-4-amine (4-ANPP) intermediate involved in the preparation of fentanyl and many 
of its analogues (Figure 2) (10).  
FIGURE 2 
A possible final step of the synthesis of 4-fluoroisobutyrylfentanyl employing the acylation of 
the N-(4-fluorophenyl)-1-(2-phenylethyl)piperidin-4-amine intermediate using either isobutyryl 
chloride or isobutyric anhydride. 
 
 
Most of these synthetic procedures are relatively straightforward. Due to the typical high potency of 
fentanils there is a risk of severe poisoning following accidental exposure during their manufacture. 
Extreme care must be taken when carrying out the final synthetic step as well as when purifying and 
handling the substances. Likewise, accidental exposure to the fentanils could pose a risk of poisoning 
to the public, law enforcement, emergency personnel, as well as medical and forensic laboratory 
personnel. In addition to exercising extreme caution when handling materials suspected to contain 
fentanils, personnel should be equipped with appropriate protective equipment. The antidote naloxone 
should be readily available to personnel in sufficient quantities; training in resuscitation, including the 
administration of naloxone, should also be available (IAB, 2017 US CDC, 2013; US CDC, 2016; US 
DEA, 2017a). Any required responses should continue to ensure the delivery of prompt and 
appropriate care to patients with suspected overdose (Cole & Nelson, 2017; Lynch, Suyama, & 
Guyette, 2017). 
                                                          
(10) Methods not relying on the controlled precursor NPP for the synthesis of 4-fluoroisobutyrylfentanyl are possible. For 
example, alkylation of N-(4-fluorophenyl)-2-methyl-N-(piperidin-4-yl)propanamide by phenethyl chloride would afford the title 
product. 
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In contrast to the 4-ANPP and its precursor N-phenethyl-4-piperidone (NPP), which were scheduled in 
2017 and are listed in Table I of the United Nations Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988 (CND, 2017; INCB, 2017), the fluorinated analogue of 4-ANPP used 
for the preparation of 4-fluoroisobutyrylfentanyl is not an internationally controlled substance.  
Typical impurities encountered in seized and collected samples 
There are no quantitative data available on the impurities detected in seized and collected samples 
reported to the EMCDDA (Section C). A potentially detectable impurity might be predicted to include 
the N-(4-fluorophenyl)-1-(2-phenylethyl)piperidin-4-amine intermediate . 
A1.2. Physical/pharmaceutical form  
Data from seizures and collected samples reported to the EMCDDA have noted that 4-
fluoroisobutyrylfentanyl has typically been detected in powders, tablets and liquids (Section C).  
A1.3. Route of administration and dosage  
As with other fentanils, 4-fluoroisobutyrylfentanyl can be administered orally as a powder (including in 
capsules), as tablets, or as a solution (using nasal sprays) or by insufflation of a powder; it can also 
be administered intranasally or sublingually via a spray; inhaled by smoking or vaporizing; and, 
administered by injection (intravenous and intramuscular). There are also instances where 4-
fluoroisobutyrylfentanyl is advertised for sale in the form of blotters by Internet vendors. Users have 
also described rectal administrations (11). 
Of note is the apparent popularity of selling ready-to-use or homemade nasal sprays containing 
solutions for the administration of fentanils. It is worth noting that some of these products are not 
always labelled and/or sold as another substance, a phenomenon that extends to the use of other 
fentanils that have appeared in Europe in the past few years, including acryloylfentanyl (EMCDDA 
2017b; EMCDDA 2017d; Ujváry et al., 2017) and furanylfentanyl (EMCDDA, 2017c; EMCDDA, 
2017e).  
Dosage 
Limited information is available regarding the dose and the dose regimens of 4-
fluoroisobutyrylfentanyl. Reports available on user discussion forums included single intravenous 
administrations up to 5 mg followed by nasal spray administrations reportedly amounting to 3 mg over 
a six-hour period (12). Other examples included nasal administrations of 5 mg per day (13); “dosing 
every 2-3 hours (0.7 mg/mL)… up to about 0.35 mg IV” (11); 0.1–0.5 ml intravenous injections of 0.69 
mg/mL solutions and 2 mL rectal administrations using the same concentration (11); self-prepared 
nasal spray concentrations of 10–15 mg/mL have also been mentioned (14). 
From this, however, it is not possible to discern the ‘typical’ dosages administered by users. Doses 
appear to differ depending on factors such as the route of administration, the tolerance of the users, 
the use of other drugs, and the desired effects. 
                                                          
(11) http://www.bluelight.org/vb/threads/774831-Novel-opioid-4-Fluoroisobutyrfentanyl-(4-FiBF-p-FiBF)/page2 (last accessed: 
22.10.2017). 
(12) https://erowid.org/experiences/exp_pdf.php?ID=106906&format=pdf (last accessed 21.10.2017).  
(13) http://www.bluelight.org/vb/threads/774831-Novel-opioid-4-Fluoroisobutyrfentanyl-(4-FiBF-p-FiBF) (last accessed 
21.10.2017). 
(14) https://www.reddit.com/r/opiates/comments/3ved25/anybody_try_furanylfentanyl_fuf_or/ (last accessed 21.10.2017). 
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A2. Pharmacology, including pharmacodynamics and pharmacokinetics  
Pharmacologically, 4-fluoroisobutyrylfentanyl is an opioid receptor agonist. 
Pharmacodynamics 
In vitro studies 
The currently available data suggests that 4-fluoroisobutyrylfentanyl binds to the μ-opioid receptor 
(MOR) with high selectivity over the κ- and δ-opioid receptors (KOR and DOR) (Table 2) (15) (US 
DEA, 2017b).  
Table 2 provides a summary of binding and functional activity data that illustrate that 4-
fluoroisobutyrylfentanyl (EC50 = 115 nM, [
35S]GTPγS binding assay, Emax = 91.6%) functioned as a 
MOR agonist (16). In comparison, morphine (EC50 = 17.2 nM, [
35S]GTPγS binding assay, Emax = 
86.1%) and fentanyl (EC50 = 28.8 nM, Emax = 94.0%) were several times more potent than 4-
fluoroisobutyrylfentanyl and all three test drugs exhibited comparable efficacy (Emax) using this 
particular in vitro assay. 
4-Fluoroisobutyrylfentanyl showed relatively low affinity toward KOR (Ki = 2,700 nM) with moderate to 
low potency and moderate relative efficacy (EC50 = 1,330 nM, [
35S]GTPγS binding assay, Emax = 
49.3%). As far as DOR was concerned, binding affinity and potency were relatively low, whereas 
efficacy was moderate (Ki = 1,670 nM, EC50 = 2,490 nM, [
35S]GTPγS binding assay, Emax = 64%), 
which suggested a MOR selective profile, at least under these in vitro conditions. All test drugs used 
as positive control were shown to be efficacious agonists (Table 2). 
TABLE 2  
Binding and functional activity data for 4-fluoroisobutyrylfentanyl (4F-iBF) generated via the 
Drug Enforcement Administration–Veterans Affairs (DEA-VA) Interagency Agreement 
(modified from US DEA, 2017b). 
MOR 4F-iBF b DAMGO Morphine Fentanyl Naltrexone 
[3H]DAMGO 
binding Ki (nM) 
0.451 ± 0.046 0.277 ± 0.027 0.322 ± 0.048 0.144 ± 0.024 0.082 ± 0.011 
IC50 (nM) 2.16 ± 0.20 – – – – 
[35S]GTPγS 
binding 
4F-iBF b DAMGO Morphine Fentanyl  
Stimulation EC50 
(nM) 
115 ± 33 22.4 ± 7.0 17.2 ± 4.5 28.8 ± 6.9 – 
Maximal 
stimulation (%)* 
91.6 ± 4.1 96.1 ± 2.2 86.1 ± 5.0 94.0 ± 6.0 – 
DOR 4F-iBF b DPDPE-OH Morphine Fentanyl Naltrexone 
[3H]DPDPE 
binding Ki (nM) 
1,670 ± 410 1.93 ± 0.14 79.1 ± 5.1 164 ± 13 8.7 ± 1.0 
                                                          
(15) Ki represents the equilibrium inhibition constant for the test drug displacing the radioligand. 
(16) EC50 represents the concentration that causes a half-maximal response of the agonist.  
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IC50 (nM) 2,790 ± 630 – – – – 
[35S]GTPγS 
binding 
4F-iBF b DPDPE-OH Morphine Fentanyl  
Stimulation EC50 
(nM) 
2,490 ± 390 7.4 ± 1.6 750 ± 160 996 ± 99 – 
Maximal 
stimulation (%)* 
64 ± 15 98.90 ± 0.76 64.0 ± 9.7 42.5 ± 3.6 – 
KOR 4F-iBF b U-50,488H Morphine Fentanyl Nor-BNI 
[3H]U-69,593 
binding Ki (nM) 
2,700 ± 490 0.143 ± 0.043 34.9 ± 7.0 224 ± 36 0.53 ± 0.17 
IC50 (nM) 4,830 ± 790 – – – – 
[35S]GTPγS 
binding 
4F-iBF b U-50,488H Morphine Fentanyl – 
Stimulation EC50 
(nM) 
1,330 ± 290 1.89 ± 0.30 81 ± 10 347 ± 65 – 
Maximal 
stimulation (%)* 
49.3 ± 5.8 98.1 ± 1.2 87.3 ± 6.7 74.9 ± 9.0 – 
a In receptor binding experiments, transfected Chinese hamster ovary (CHO) cells expressing human δ- and κ-opioid receptors 
and rat μ-opioid receptors were used. Experimental details for functional activity studies are not reported. DOR: delta opioid 
receptor; KOR: kappa opioid receptor; MOR: mu opioid receptor; DAMGO: Tyr-Ala-Gly-N-Me-Phe-Gly-ol, DPDPE: Tyr-Pen-Gly-
Phe-Pen [disulfide bridge: 2-5]; U-69,593: (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-
benzeneacetamide; U-50,488H: trans-(±)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide 
methanesulfonate salt; Nor-BNI: norbinaltorphimine; U-69,593: (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-
8-yl]-benzeneacetamide. SEM: standard error of the mean.  
Numbers represent the means ± SEM from at least three independent experiments, each conducted with duplicate 
determinations. Standard compounds are the agonists DPDPE (delta), U-50,488H (kappa) and DAMGO (mu) and the 
antagonists naltrexone (delta and mu) and nor-BNI (kappa). 
* Maximal stimulation by test compound is normalized to the maximal stimulation by DPDPE (delta), U50,488H (kappa) or 
DAMGO (mu) above basal.  
b 4F-iBF: 4-fluoroisobutyrylfentanyl. 
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Animal studies 
It has recently been reported that 4-fluoroisobutyryfentanyl showed analgesic effects in mice 
(subcutaneous administration) in the tail-flick test (55°C). The ED50 value for 4-fluoroisobutyryfentanyl 
was determined at 1.61 mg/kg, compared to 0.122 mg/kg for fentanyl, and 12 mg/kg for morphine. It 
was furthermore reported that naltrexone administration (10 mg/kg, s.c.) affected nociceptive effects 
as demonstrated by a corresponding shift of the dose-response curve to the right (WHO, 2017) (17).  
Pharmacokinetics 
A recent in vitro investigation using human hepatocytes (10 μM test drug, up to 5 h incubation time) 
identified 17 metabolites (Figure 3). The identified biotransformations included N-dealkylation (C3), 
hydroxylation (C7, C8, C10, C11, C15, C17) followed by glucuronidation (C5), dihydroxylation (C9), 
dihydrodiol formation (C4), dihydroxylation with methylation (C12, C13) followed by glucuronidation 
(C6), amide hydrolysis (C14), oxidative N-dealkylation, and further reduction of the keto group (C1), 
carboxylation (C2), and carbonylation (C16) (Figure 3) (Watanabe et al., 2017).  
The parent drug was prevalent in both the hepatocyte incubate and authentic human urine samples. 
Nine metabolites were observed in hepatocytes (C3, C8, C10, C12, C14–C17) with the desphenethyl 
(“nor”) metabolite C3 (18) being the major metabolite in the 5 h sample followed by the 
monohydroxylated metabolites C15 and C10. Eleven metabolites were detected in hydrolysed urine 
(C1, C2, C3, C4, C7, C9–C13, C15), which suggested that major metabolites were comparable. The 
C12 metabolite, a potential target for confirming consumption of 4-fluoroisobutyrylfentanyl, was also 
identified (Watanabe et al., 2017). 
 
 
 
 
 
 
 
 
 
 
 
                                                          
(17) Data provided by the US Drug Enforcement Administration, Food and Drug Administration, National Center for Toxicological 
Research (2017b). Report: 4-Fluoroisobutyryl fentanyl (FIBF), Evaluation of analgesic effects using the warm water tail 
withdrawal assay. 28 June 2017. 
(18) Systematic name: N-(4-Fluorophenyl)-2-methyl-N-(piperidin-4-yl)propanamide. 
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FIGURE 3 
Proposed metabolic pathway of 4-fluoroisobutyrylfentanyl suggested by Watanabe et al. 
(2017), which summarize the results obtained from in vitro incubations with 10-donor pooled 
human hepatocytes and authentic human urine samples. Enclosed metabolites: major 
metabolites detected in hydrolysed human urine specimen; metabolites in italics only found in 
either the in vitro or in vivo experiment. 
 
A limited number of self-reported user experiences have noted that the duration of effects induced by 
4-fluoroisobutyrylfentanyl could be greater than 12 hours (19,20). If correct, then this would indicate a 
longer lasting activity compared to fentanyl and other fentanyl analogues available on the market. As 
noted in the introduction, given the difficulties of collecting such data, these reports should be viewed 
with caution. 
Inter-individual genetic variability in metabolising enzymes 
For fentanyl, oxidative dealkylation by hepatic CYP3A4 and by CYP3A5 isoenzymes to norfentanyl 
has been demonstrated (Guitton et al., 1997, Jin et al., 2005, Labroo et al., 1997). The variation of the 
expression of the genes coding for these CYP3A isoenzymes among populations might be of clinical 
significance (Meyer and Maurer, 2011) but further studies are needed to address the toxicological 
consequences of such polymorphisms.    
                                                          
(19) https://forum.drugs-and-users.org/index.php?topic=3373.0 (last accessed 22.10.2017). 
(20) http://www.bluelight.org/vb/threads/774831-Novel-opioid-4-Fluoroisobutyrfentanyl-(4-FiBF-p-FiBF) 
 (last accessed 22.10.2017). 
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Interactions with other substances and other interactions  
Specific information about 4-fluoroisobutyrylfentanyl could not be identified although it seems 
conceivable that interactions observed with fentanyl might equally apply (Preston, 2016). For 
example, should 4-fluoroisobutyrylfentanyl undergo oxidative dealkylation by hepatic CYP3A4 and by 
CYP3A5 isoenzymes then the use of this substance with inhibitors of these isoenzymes, such as 
clarithromycin, erythromycin, fluconazole, grapefruit juice, indinavir, itraconazole, ketoconazole, 
nefazodone, ritonavir, saquinavir, suboxone, verapamil) (21) may result in increased plasma 
concentration of 4-fluoroisobutyrylfentanyl. This could increase the risk of poisoning, including 
potentially fatal respiratory depression.  
The concomitant use of other central nervous system (CNS) depressants, including other opioids, 
sedatives/hypnotics (such as the benzodiazepines and the z-drugs), ethanol, pregabalin, gabapentin, 
tranquillisers, and sedating anti-histamines, may produce additive depressant effects.  
The use of fentanyl with serotoninergic agents, such as selective serotonin re-uptake Inhibitors 
(SSRIs) (the most commonly prescribed antidepressants) or serotonin norepinephrine re-uptake 
inhibitors (SNRIs) or monoamine oxidase inhibitors (MAOIs) has been associated with a serotonin 
syndrome, a potentially life-threatening condition. This association is likely to extend to illicit drugs, 
which act on the serotonergic system. It is not known if this association is also seen with 4-
fluoroisobutyrylfentanyl.  
Effects on ability to drive and operate machines 
No studies of the effects of 4-fluoroisobutyrylfentanyl on the ability to drive and operate machines 
have been performed. However, it is well established that opioid analgesics, such as fentanyl, impair 
the mental and physical ability required to drive and operate machines. This effect is likely to extend 
to 4-fluoroisobutyrylfentanyl. 
A3. Psychological and behavioural effects 
Information on the psychological and behavioural effects of 4-fluoroisobutyrylfentanyl is limited. It 
appears that the psychoactive profile of 4-fluoroisobutyrylfentanyl might share at least some 
similarities with other opioid analgesics such as fentanyl and heroin. These would include relaxation 
and euphoria; at higher doses, sedation and profound intoxication may occur. 
A limited number of self-reported user experiences have noted that 4-fluoroisobutyrylfentanyl is ‘long 
lasting’ and is less euphorigenic when compared to other opioids (22,23,24). As noted in the introduction, 
given the difficulties of collecting such data, these reports should be viewed with caution. In addition, it 
should be noted that if 4-fluoroisobutyrylfentanyl was indeed less euphorigenic, this might lead to 
users increasing the dose, which could increase the risk of opioid toxicity and particularly life-
threatening respiratory depression. 
 
                                                          
(21) For a more comprehensive list of drug interactions with fentanyl, see, for example, 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124&source
=homeMedSearch&keyword=fentanyl&category=human&isNewQuery=true 
(22) https://forum.drugs-and-users.org/index.php?topic=3373.0 (last accessed 22.10.2017). 
(23) http://www.bluelight.org/vb/threads/774831-Novel-opioid-4-Fluoroisobutyrfentanyl-(4-FiBF-p-FiBF) (last accessed 
22.10.2017). 
(24) https://www.reddit.com/r/opiates/comments/3ved25/anybody_try_furanylfentanyl_fuf_or/ (last accessed 22.10.2017). 
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A4. Legitimate uses of the product  
4-Fluoroisobutyrylfentanyl is used as an analytical reference material in clinical and forensic case 
work/investigations as well as scientific research. There is currently no information that suggests 4-
fluoroisobutyrylfentanyl is used for other legitimate purposes. 
There are no reported uses of 4-fluoroisobutyrylfentanyl as a component in industrial, cosmetic or 
agricultural products. In addition, a search of the Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) registered substances database hosted by the European 
Chemicals Agency (ECHA) using the CAS Registry Number returned no results. 
There is no marketing authorisation (existing, on-going or suspended) for 4-fluoroisobutyrylfentanyl 
neither in the European Union nor in the Member States that responded to the request for information 
from the European Medicines Agency, which was undertaken as part of the Joint Report process 
(EMCDDA, 2017a) 
There is no information to suggest that 4-fluoroisobutyrylfentanyl is currently used in the manufacture 
of a medicinal product in the European Union. However, in the absence of a database on the 
synthetic routes of all medicinal products it is not possible to confirm whether or not 4-
fluoroisobutyrylfentanyl is currently used in the manufacture of a medicinal product.  
Section B. Dependence and abuse potential 
B1. Animal data  
No studies were identified that have investigated the dependence and/or abuse potential of 4-
fluoroisobutyrylfentanyl in animal models. 
The related des-fluoro analogue, isobutyrylfentanyl (NIH 10487) (Aceto et al., 1988) was studied in 
rhesus monkeys that received 3.0 mg/kg s.c. of morphine sulfate every 6 h for at least 90 days. In the 
single dose substitution test in rhesus monkeys, NIH 10487 (evaluated at 0.025 mg/kg and 0.1 mg/kg) 
“substituted completely for morphine. Potency estimate is 30 times [that of] morphine. Rapid onset 
and 2.5h duration of action were observed. Sagging, ataxia, slowing and scratching were noted at the 
highest dose during the first hour”. 
B2. Human data  
No studies were identified that have investigated the dependence and/or abuse potential of 4-
fluoroisobutyrylfentanyl in humans.  
Whereas no specific data exist for 4-fluoroisobutyrylfentanyl, it is well established that opioid 
analgesics such as fentanyl have an abuse liability and can induce tolerance and dependence. 
Research is required in order to examine these effects with 4-fluoroisobutyrylfentanyl. 
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Section C. Prevalence of use 
Information from seizures, collected and biological samples 
4-Fluoroisobutyrylfentanyl was formally notified on 26 August 2016 by the EMCDDA on behalf of the 
Slovenia, in accordance with Article 4 of the Council Decision. The Reporting Form details a collected 
sample of 5 grams of white powder that was test-purchased as part of the EU co-funded RESPONSE 
project, and analysed on 25 May 2016 in Ljubljana. 4-Fluoroisobutyrylfentanyl was analytically 
confirmed by GC-MS, HPLC-TOF, FTIR-ATR, GC-MS-IR, ion chromatography and NMR by the 
Slovenian National Forensic Laboratory and the Faculty of Chemistry and Chemical technology of the 
University of Ljubljana (EMCDDA, 2017a). 
Since then, a total of 5 Member States (Belgium, Germany, Slovenia, Sweden and the United 
Kingdom) have reported detections (25) of 4-fluoroisobutyrylfentanyl (EMCDDA, 2017a). 
It is important to note that detections of 4-fluoroisobutyrylfentanyl may be under-reported since the 
substance is not routinely screened for. Three Member States (Austria, Slovenia and Sweden) and 
Norway reported that 4-fluoroisobutyrylfentanyl is part of routine screening in some (but not all) 
laboratories. 
Information from seizures 
Information reported to the EMCDDA and Europol indicates that 24 seizures of 4-
fluoroisobutyrylfentanyl have been reported by 4 Member States: Sweden (20 seizures), Belgium (1), 
Germany (1), and the United Kingdom (2). The majority of the seizures took place in 2016, while the 
most recent events took place in 2017. 
Additionally, Finland reported a seizure of 0.05 g of a powder which was reported as ‘2F-, 3F- or 4F-
BF; 2F-, 3F- or 4F-iBF’, as the exact isomer was not be determined. This case is not discussed further 
in this report. 
No information regarding the purity of the samples was provided. 
Powders 
A total of 9 seizures of powders were reported by: Belgium, Germany, Sweden, and the United 
Kingdom, amounting to a total of 378.6 g. 
The powder seizure reported by Germany also contained furanylfentanyl. In one case reported by the 
United Kingdom, the powder also contained furanylfentanyl and an unspecified isomer of 
‘fluorofentanyl’. 
In the other seizure reported by the United Kingdom, a number of different items were seized, and 
different substances identified, including heroin, cocaine, steroids and synthetic cannabinoids (5F-
MDMB-PINACA and MMB-FUBINACA). Nine of the items were found to contain 4-
fluoroisobutyrylfentanyl, as follows:  
 0.436 grams of crystalline powder which appeared to be pure 4-fluoroisobutyrylfentanyl (no 
other compounds detected in the crystals); 
                                                          
(25) ‘Detections’ is an all-encompassing term and may include seizures and/or collected and/or biological samples that are 
analytically confirmed. Seizure means a substance available (seized) through law enforcement activities (police, customs, 
border guards, etc.). Collected samples are those that are actively collected by drug monitoring systems (such as test 
purchases) for monitoring and research purposes. Biological samples are those from human body fluids (urine, blood, etc.) 
and/or specimens (tissues, hair, etc.) 
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 0.425 grams of brown powder, found to contain mainly 4-fluoroisobutyrylfentanyl mixed with 
smaller amounts of paracetamol and caffeine;  
 7 items, consisting of heroin containing paracetamol, caffeine and 4-fluoroisobutyrylfentanyl. 
These were of various strengths of heroin and 4-fluoroisobutyrylfentanyl which were not 
determined. The total weight of these powders was 105.8 g. 
Other physical forms 
Sweden reported seizures of 4-fluoroisobutyrylfentanyl in tablets and liquids, as follows: 
 12 seizures of tablets, amounting to a total of 6727 tablets; 
 3 seizures of liquids, amounting to a total of 208 millilitres. 
Information from collected samples 
Slovenia reported a sample of 5 g of 4-fluoroisobutyrylfentanyl base in powder form which was 
purchased from an Internet vendor. The sample was apparently shipped from China and was 
received in May 2016. No other substances were detected in the sample. 
Information from biological samples 
Serious adverse events (deaths and acute intoxications) with confirmed exposure to 4-
fluoroisobutyrylfentanyl from biological samples are discussed in Section D. 
Availability, supply, price 
Information on production 
No information was received in relation to the production of 4-fluoroisobutyrylfentanyl. 
Information on trafficking 
No information was reported to the EMCDDA in relation to the trafficking of 4-fluoroisobutyrylfentanyl. 
Information on the source of 4-fluoroisobutyrylfentanyl is limited to one report regarding collected 
sample of the substance. Here, the substance was ordered from an online vendor apparently based in 
China (see above). In addition, Belgium reported a seizure of 4-fluoroisobutyrylfentanyl to the 
EMCCDA where the final destination was Germany. 
Availability from Internet vendors 
A structured search of online vendors on the surface web by the EMCDDA (26) found that the 
substance is offered for sale online in small and wholesale amounts, typically as a ‘research chemical’ 
and as powders, liquids, and blotters. 
On the websites identified, 4-fluoroisobutyrylfentanyl was available in powder, liquid and blotter form. 
For powders, amounts on sale ranged from 0.5 grams to 10 kg, for liquids 5 to 50 mL and for blotters 
1 to 500 units. Prices varied according to the amounts on sale. Powders ranged from EUR 0.7 per 
gram to EUR 238 per gram. Liquids and blotters were only sold in one internet retailer. The price of 
the liquids varied from EUR 1 to EUR 5 per mL; for blotters a price of EUR 1 per unit was indicated. 
The availability of 4-fluoroisobutyrylfentanyl on the darknet is not currently known. 
                                                          
(26) The search for online vendors of 4-fluoroisobutyrylfentanyl on the surface web was performed on 06/06/2017 using 
previously established methodology (EMCDDA, 2017c). The search identified 31 vendors that appeared to be based in, and/or 
claim to have presence in China (n=18), India (n=3), USA (n=2), Hong Kong (n=2), Hungary (n=1), Sweden (n=1), Turkey (n=1) 
and European Union (not specified) (n=1); the remaining 2 websites did not list a location. Nineteen websites listed quantities 
and prices for4-fluoroisobutyrylfentanyl. The remaining websites only provided prices on request. 
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Prevalence of use  
No studies were identified that have investigated the prevalence of use of 4-fluoroisobutyrylfentanyl in 
the general population. Given its pharmacology and that it is sold openly as a ‘legal’ replacement to 
illicit opioids, it would be expected that users looking for substitutes for opioids, which would include 
individuals who use illicit opioids, such as heroin and/or prescription opioids, may seek out 4-
fluoroisobutyrylfentanyl and other fentanils. It also appears that there is interest in this substance by 
some psychonauts. Overall, the available information does not suggest widespread use of the 
substance. 
Of additional note is that, in the past few years, fentanils have been sold in Europe as ready-to-use 
nasal sprays. In some cases they have also been sold as e-liquids for vaping. In general, these novel 
products could make it easier to use such substances (with similar effects to injecting) and make them 
more socially acceptable, potentially expanding their use in new user groups. These are new 
developments that will require careful monitoring. 
Section D. Health risks 
D1. Acute health effects 
D1.1. Animal data 
Data on the acute toxicity, abuse liability, and dependence producing potential of 4-
fluoroisobutyrylfentanyl could not be identified.  
D1.2. Human data 
No clinical studies were identified that have examined the acute health effects of 4-
fluoroisobutyrylfentanyl and/or its metabolites in humans. Although the pharmacology and toxicology 
of 4-fluoroisobutyrylfentanyl remains largely unstudied, the available data suggests that the nature of 
its effects share some similarities with opioid analgesics such as morphine and fentanyl. The acute 
effects of these types of opioids include: euphoria, relaxation, analgesia, sedation, bradycardia, 
hypothermia, miosis, and respiratory depression or arrest. They also have an abuse liability and 
dependence potential (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; Romberg et al., 2003). 
Similar to other opioid analgesics, the most serious acute health risk associated with 4-
fluoroisobutyrylfentanyl use is probably respiratory depression, which can lead to apnoea, respiratory 
arrest and death (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; White & Irvine, 1999). This risk may 
be greater due to: the difficulty in diluting the substance; a lack of experience with its effects and 
dosing; the use of other central nervous system depressants at the same time (such as other opioids, 
benzodiazepines, gabapentanoids, and alcohol); a lack of tolerance to opioids; and, using the 
substance alone (such as at home) which would make it more difficult for users to call for help in the 
case of poisoning. 
The antidote naloxone should reverse acute poisoning caused by 4-fluoroisobutyrylfentanyl (Kim and 
Nelson, 2015). 
Recent clinical and community experience in treating poisonings caused by fentanils suggests that 
larger than normal doses and repeated doses of naloxone may be required to manage the poisoning 
in some cases; longer periods of observation may also be required (Klar et al., 2016; Moss et al., 
2017; Somerville et al., 2017; Sutter et al., 2017). 
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There is a lack of information on the clinical features of poisoning caused by 4-
fluoroisobutyrylfentanyl. Nonetheless, the available data suggests that the nature of the effects of 4-
fluoroisobutyrylfentanyl share some similarities with opioid analgesics such as morphine and fentanyl. 
As a result, features of poisoning are likely to include reduced level of consciousness or 
unconsciousness, respiratory depression and arrest, and miosis (27). 
Acute intoxications reported by the Member States 
No acute intoxications with confirmed exposure to 4-fluoroisobutyrylfentanyl were reported (27,28). 
Acute intoxications identified from other sources 
No cases of acute intoxications were identified from other sources (27). 
Deaths reported by the Member States 
A total of 20 deaths were reported by 2 Member States: Sweden (16) and the United Kingdom (4). 
Exposure to 4-fluoroisobutyrylfentanyl was analytically confirmed in post-mortem samples in all cases 
from Sweden; no reference standard was available to distinguish between 4-fluoroisobutyrylfentanyl 
and 4-fluorobutyrylfentanyl in cases from the United Kingdom.  
The deaths occurred between July 2016 and March 2017, with 17 occurring in 2016 and 3 in 2017. 
Of the 18 deaths where demographic data were available, 16 were male (80%) and 2 were female 
(20%). The mean age of the males was 35 years (median 34) and ranged from 20 to 52 years; the 
age of the females was 24 and 36 years. 
Circumstances and cause of death 
In the majority of cases there was a lack of information regarding any symptoms experienced by the 
deceased prior to death, but, where described in a few cases, the deceased had become 
unconscious and in one case the deceased was found convulsing. Where information was known, in 
the majority of instances the individuals were found dead, predominantly in a home environment 
(either their own or a friend’s). Consequently, it was not possible to identify or evaluate ante-mortem 
symptoms (especially in relation to acute intoxication) in these cases. 
The cause of death was reported in 16 out of 20 cases. In at least 13 deaths, intoxication with 4-
fluoroisobutyrylfentanyl was reported either as the primary cause of death or as likely to have 
contributed to death (even in presence of other substances); other substances were detected in 19 
cases (with creatinine detected in the remaining case). 
                                                          
(27) Information on the clinical features of intoxication caused by 4-fluoroisobutyrylfentanyl is limited to a single report involving a 
death published by Helander et al., (2017). In this case, a male user had apparently injected intravenously 250 mg of 4-
fluoroisobutyrylfentanyl and was ‘discovered lifeless’. The main features reported were unconsciousness, apnoea, and 
asystole. The patient ‘was discovered lifeless with a syringe reportedly containing “4-iBF” next to him. Cardiopulmonary 
resuscitation (CPR) was initiated by relatives. On ambulance arrival, the first recorded rhythm was asystole and CPR was 
maintained with an automated device. He was given 0.4mg of naloxone and repeated 1mg doses of adrenaline intravenously. 
Palpable pulses appeared only transiently and CPR was maintained during transport to hospital. Return of spontaneous 
circulation occurred after 90 min of CPR. The patient was unconscious (RLS 8), had dilated pupils unresponsive to light, and 
was normothermic. He was intubated, put on ventilator, and mildly therapeutically cooled to the target 36 (C (96.8 (F) body 
temperature, according to hospital guidelines. An early computed tomography (CT) showed brain edema. His neurological 
condition did not improve during the following 24 h and he was declared dead 43 h after arriving to hospital’ (Helander et al., 
2017). This case is included in the deaths reported by the Member States. 
(28) Sweden reported 2 acute intoxications with suspected exposure to 4-fluoroisobutyrylfentanyl. These cases are not 
discussed further in this report. 
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4-Fluoroisobutyrylfentanyl was quantified in 16 cases. Post-mortem femoral blood concentrations 
ranged from 0.76 to 370 ng/g blood (median 41 ng/g blood). In 2 cases, although the concentration 
was measured (44 and 85 ng/mL), it was not possible to determine if it related to 4-
fluoroisobutyrylfentanyl or 4-fluorobutyrylfentanyl. Due to the toxicity of potent opioids and variability in 
user tolerance, determination of a ‘fatal’ concentration based on a post-mortem blood concentration is 
not reliable. In the majority of circumstances involving fentanils, the mere presence of the drug is of 
significance whether concentration has been determined or not, especially in situations of poly-drug 
use. 
A range of other substances were detected in the deaths, including: cannabinoids, benzodiazepines, 
amphetamine, zopiclone, zolpidem, gabapentinoids (pregabalin and gabapentin), antidepressants, 
antipsychotics, antihistamines, a synthetic cathinone (alpha-PHP), ketamine and ethanol. Other 
opiates/opioids were detected in 9 of the deaths; codeine, buprenorphine, tramadol, methadone, 
oxycodone, fentanyl, despropionylfentanyl, tetrahydrofuranylfentanyl, and acryloylfentanyl. 
Overall, whilst other substances may have contributed some toxicity, a synergistic effect with 4-
fluoroisobutyrylfentanyl would have been likely with other central nervous system depressants such 
as ethanol, benzodiazepines, opioids, etc. Nevertheless, the potent opioid nature of 4-
fluoroisobutyrylfentanyl means that the primary toxic contribution could be attributed to 4-
fluoroisobutyrylfentanyl and death may not have occurred if 4-fluoroisobutyrylfentanyl had not been 
used. An assessment of the Toxicological Significance Score (TSS) (Elliott, Sedefov, & Evans-Brown, 
2017) incorporating the above considerations shows that 4-fluoroisobutyrylfentanyl had a TSS value 
of 3 (high) in 15 out of 16 of the deaths (where it was cited as the cause of death or is likely to have 
contributed to death). In the remaining death, an alternative cause of death (drowning) was cited (TSS 
value of 1, low). The 4 cases where 4-fluoroisobutyrylfentanyl could not be unequivocally confirmed 
were not part of the assessment. 
Deaths identified from other sources 
Since August 2016, more than 60 deaths associated with 4-fluoroisobutyrylfentanyl have been 
reported in the United States (US DEA, 2017b). 
D2. Chronic health effects 
D2.1. Animal data 
No studies were identified that have investigated the chronic health effects of 4-
fluoroisobutyrylfentanyl in animals. 
D2.2. Human data 
No studies were identified that have investigated the chronic health effects of 4-
fluoroisobutyrylfentanyl in humans. 
D3. Factors affecting public health risks 
D3.1. Availability and quality of the new psychoactive substance on the market  
4-Fluoroisobutyrylfentanyl is being sold on the surface web as a drug in its own right. It is sold in both 
retail and wholesale quantities. It has been sold as a ‘research chemical’ in powder form, liquids, and 
blotters. 
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4-Fluoroisobutyrylfentanyl is also used to make tablets, as evidenced by the 12 seizures by Swedish 
Police of 6727 tablets. No further details are available on these cases. 
Information from a seizure case in the United Kingdom suggests that 4-fluoroisobutyrylfentanyl has 
been sold on the illicit opioid market in mixtures with heroin. 
D3.2. Availability of the information, degree of knowledge and perceptions amongst users 
concerning the psychoactive substance and its effects 
Due to its relatively recent availability on the drug market, the availability of information, degree of 
knowledge and perceptions amongst users concerning 4-fluoroisobutyrylfentanyl and its effects are 
limited. 
D3.3. Characteristics and behaviour of users  
No studies were identified that have examined the characteristics and behaviours of users of 4-
fluoroisobutyrylfentanyl. Section C (above) and Section E6 (below) provides additional information on 
the likely user groups of 4-fluoroisobutyrylfentanyl. 
D3.4. Nature and extent of health consequences 
Acute health risks 
Although the pharmacology and toxicology of 4-fluoroisobutyrylfentanyl remains largely unstudied, 
the available data suggests that the nature of its effects share some similarities with opioid analgesics 
such as morphine and fentanyl.  
The acute effects of these types of opioids include: euphoria, relaxation, analgesia, sedation, 
bradycardia, hypothermia, and respiratory depression. They also have an abuse liability and 
dependence potential (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; Romberg et al., 2003). 
Similar to other opioid analgesics, the most serious acute risk arising from the use of 4-
fluoroisobutyrylfentanyl is probably from respiratory depression, which can lead to apnoea, respiratory 
arrest, and death (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; White & Irvine, 1999).  
In general, this risk may be exacerbated by:  
 the difficulty in diluting/using fentanils (as they are typically highly potent), which can lead to a 
toxic dose being accidentally used (de Boer et al., 2003; Sutter et al., 2017); 
 the apparent rapid onset of severe poisoning following use (Somerville et al., 2017); 
 central nervous system (such as injecting, insufflation, and inhalation) (Macleod et al., 2012);  
 availability of easy to use dosage forms (such as nasal sprays and e-liquids); 
 use of other central nervous system depressants (such as other opioids, benzodiazepines, 
and alcohol) (e.g. van der Schrier et al., 2017) ;  
 lack of tolerance to opioids in opioid-naïve persons (such as new or former users); 
 use in environments where it may be difficult to summon help in the event of poisoning (e.g. 
alone in a home environment) (Somerville et al., 2017); 
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 limited availability of the antidote naloxone in community settings (EMCDDA, 2015; EMCDDA, 
2016b; Somerville et al., 2017). 
In addition, and, often unknown to users, the fentanils are sold as heroin or mixed with heroin. They 
are also used to make counterfeits of highly sought-after analgesics and benzodiazepines. They have 
also been sold in or as drugs such as cocaine (Klar et al., 2016; SFDPH, 2015; Sutter et al., 2017; 
Tomassoni et al., 2017). Due to this, users may not be aware that they are using a fentanil; in some 
cases these individuals will have no tolerance to opioids nor access to community naloxone 
programmes. Overall, these factors may increase the risk of life-threatening poisoning. 
Given the above risks, poisonings by fentanils may manifest as outbreaks which have the potential to 
overwhelm emergency responders and other local healthcare systems (Klar et al., 2016; SFDPH, 
2015; Sutter et al., 2017; Tomassoni et al., 2017). 
Accidental exposure to the fentanils may also pose a risk to non-users, including family and friends, 
law enforcement and emergency responders. Such risks may need to be assessed so that, where 
required, appropriate procedures, training and environmental and personal protective measures can 
be provided for handling materials suspected to contain these substances (US CDC, 2016; Moss et 
al., 2017; US DEA, 2017a). Any required responses should continue to ensure the delivery of prompt 
and appropriate care to patients with suspected overdose (Cole & Nelson, 2017; Lynch, Suyama, & 
Guyette, 2017). 
Managing poisoning 
The antidote naloxone should reverse acute poisoning caused by 4-fluoroisobutyrylfentanyl (Kim and 
Nelson, 2015; Ujváry et al., 2017). Recent clinical and community experience in treating poisonings 
caused by fentanils suggests that larger than normal doses and repeated doses of naloxone may be 
required to manage the poisoning in some cases; longer periods of observation may also be required 
(Klar et al., 2016; Moss et al., 2017; Somerville et al., 2017; Sutter et al., 2017). This may reflect, 
among other factors, the high potency of the fentanils, their half-lives, the dose an individual is 
exposed to, and, the relatively short half-life of naloxone. 
Chronic health risks 
While there is limited data, the chronic health risks of carfentanil might share some similarities to 
opioids such as heroin and other fentanils. This may include dependence. 
D3.5. Long-term consequences of use 
While there is limited data, the chronic health risks of 4-fluoroisobutyrylfentanyl might share some 
similarities to opioids such as heroin and other fentanils. This may include dependence. 
D3.6. Conditions under which the new psychoactive substance is obtained and used, including 
context-related effects and risks 
There is limited data on the conditions under which 4-fluoroisobutyrylfentanyl is obtained and used. 4-
Fluoroisobutyrylfentanyl is offered for sale on the surface web as a powder, liquids, and blotters. 
It has also been seized as tablets. Information from a seizure case in the United Kingdom suggests 
that 4-fluoroisobutyrylfentanyl has been sold on the illicit opioid market in mixtures with heroin. 
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Section E. Social risks 
While there have been no studies on the social risks of 4-fluoroisobutyrylfentanyl, it is likely that some 
of the risks are similar to those associated with illicit opioids, including fentanyl and heroin. 
E1. Individual social risks 
There is no information on the individual social risks that may be associated with the use of 4-
fluoroisobutyrylfentanyl. Given that 4-fluoroisobutyrylfentanyl appears to act as an opioid analgesic, 
any such risks may have some similarities with those associated with illicit opioids. These may 
negatively impact on education or career, family or other personal and social relationships and may 
result in marginalisation. 
E2. Possible effects on direct social environment  
There is no information on the possible effects of 4-fluoroisobutyrylfentanyl on the direct social 
environment. Given that 4-fluoroisobutyrylfentanyl appears to act as an opioid analgesic, any such 
effects may have some similarities with those associated with the use of illicit opioids. 
E3. Possible effects on society as a whole 
There is no specific information on the possible effects of 4-fluoroisobutyrylfentanyl on society as a 
whole.  
As discussed above, accidental exposure to the fentanils may pose a risk of poisoning to those who 
may come into contact with the substances. This includes the family and friends of users, law 
enforcement, emergency personnel, medical and forensic laboratory personnel as well as custodial 
settings and postal services. Where required, these risks should be assessed and appropriate 
procedures, training, and protective measures should be implemented. This may include training in 
managing poisoning, including in resuscitation and adequate provision of naloxone to reverse 
poisoning. Any required responses should continue to ensure the delivery of prompt and appropriate 
care to patients with suspected overdose (Cole & Nelson, 2017; Lynch, Suyama, & Guyette, 2017). 
E4. Economic costs 
There are no data on the health and social costs related to 4-fluoroisobutyrylfentanyl. 
E5. Possible effects related to the cultural context, for example marginalisation 
There are no data on the possible effects of 4-fluoroisobutyrylfentanyl related to the cultural context. 
E6. Possible appeal of the new psychoactive substance to specific population groups 
within the general population 
While no specific examples are available on the possible appeal of 4-fluoroisobutyrylfentanyl to 
specific user groups (aside from psychonauts), it is reasonable to assume 4-fluoroisobutyrylfentanyl 
may be sought by those looking for ‘legal’ substitutes for illicit opioids, such as heroin and/or 
prescription opioids.  
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As discussed above, the open sale of fentanils in novel dosage forms—such as ready-to-use nasal 
sprays and e-liquids for vaping—poses additional concerns. These novel forms have the potential to 
make the use of fentanils easier (with similar effects to injecting) and more socially acceptable. 
Section F. Involvement of organised crime 
F1. Evidence that criminal groups are systematically involved in production, trafficking 
and distribution for financial gain 
There is no specific information to suggest the involvement of organised crime or established criminal 
groups in the manufacture, distribution and supply of 4-fluoroisobutyrylfentanyl. 
Slovenia reported a collected sample of 4-fluoroisobutyrylfentanyl to both Europol and the EMCDDA 
where the country of origin was indicated as China. 
Belgium reported a seizure of 4-fluoroisobutyrylfentanyl to the EMCCDA where the final destination 
was Germany. 
The seizure of an illicit laboratory producing fentanils in Europe in 2013 (EMCDDA, 2017e) suggests 
that the capability to manufacture fentanils may exist within the European Union. 
F2. Impact on the production, trafficking and distribution of other substances, including 
existing psychoactive substances as well as new psychoactive substances 
No information was reported nor identified concerning the impact of 4-fluoroisobutyrylfentanyl on the 
production, trafficking and distribution of other substances, including existing psychoactive 
substances as well as new psychoactive substances. 
F3. Evidence of the same groups of people being involved in different types of crime 
No information was reported nor identified concerning evidence of the same groups of people being 
involved in different types of crime related to the availability of 4-fluoroisobutyrylfentanyl. 
F4. Impact of violence from criminal groups on society as a whole or on social groups or 
local communities (public order and safety) 
No information was reported nor identified concerning incidents of violence related to the availability 
of 4-fluoroisobutyrylfentanyl. 
F5. Evidence of money laundering practices, or impact of organised crime on other 
socioeconomic factors in society 
No information was reported nor identified concerning evidence of money laundering practices, or 
impact of organised crime on other socioeconomic factors in society related to the availability of 4-
fluoroisobutyrylfentanyl. 
 
RISK ASSESSMENT I 4F-iBF 
 
46 
 
F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial 
system)  
No information was reported nor identified concerning the economic costs and consequences related 
to the availability of 4-fluoroisobutyrylfentanyl. 
F7. Use of violence between or within criminal groups 
No information was reported nor identified concerning the use of violence between or within criminal 
groups related to the availability of 4-fluoroisobutyrylfentanyl. 
F8. Evidence of strategies to prevent prosecution, for example through corruption or 
intimidation 
No information was reported nor identified concerning evidence of strategies to prevent prosecution 
related to the availability of 4-fluoroisobutyrylfentanyl. 
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